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ABSTRACT
ANALYSIS OF N-LINKED OLIGOSACCHARIDES OF PROSTATE-SPECIFIC
ANTIGEN AND PROSTATIC ACID PHOSPHATASE IN PROSTATIC FLUIDS

Krista Yaudes White
Eastern Virginia Medical School and Old Dominion University, 2009
Director: Dr. Richard R. Drake

Presently, prostate cancer is the most common cancer afflicting men in the United
States, with serum PSA being the "gold standard" protein biomarker used in the clinic for
detecting and diagnosing prostate cancer. Nonetheless, serum PSA levels can also be
elevated in non-cancerous conditions as well, such as benign prostatic hyperplasia (BPH).
Due to this overlap, many unnecessary biopsies and radical prostatectomies occur,
leading to patient distress. Despite recent advances to clinical assays which consider
other clinical parameters, there is still a great need for improved clinical detection
methodologies for prostate cancer, including improved biomarkers. Therefore, this
research project aims to examine the N-glycosylation patterns of prostate-specific antigen
(PSA) and prostatic acid phosphatase (PAP) in prostate proximal fluids, as well as to
examine the total glycan profile for prostate proximal fluids with the intent of discovering
carbohydrate-based biomarkers for the detection of early prostate carcinomas. To this
end, preliminary glycomic and proteomic studies were completed using seminal plasma
samples, based on the disease cohorts normal, BPH, and prostate cancer. These samples
resulted in sufficient protein levels of both PSA and PAP for glycopeptide and glycomic
analyses. Furthermore, these studies led to additional knowledge of PSA and PAP
glycosylation. In addition to this sample set, pools of disease-defined expressed prostatic

secretions (EPS) were generated and subsequently analyzed for detection of both protein
levels and carbohydrate structures of PSA and PAP, as well as examined for their total
glycomic profile. We succeeded in characterizing EPS fluids for both protein and
carbohydrate content, as well as identified potential carbohydrate targets for the
generation of new clinical assays for the detection of early prostate carcinomas. These
targets are fucosylated, complex sub-type glycans which we found to be under-expressed
in prostate carcinoma samples as compared to their non-cancerous counterparts. We
believe EPS fluids have utility not only for discovery of cancer biomarkers, but also for
use in future clinical assays.
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CHAPTER I
INTRODUCTION

1.1 Prostate Cancer
Prostate cancer is the most common and second most fatal cancer afflicting men
in the United States, excluding non-melanoma skin carcinomas. It is estimated that in
2009 there were 192,280 new cases of prostate cancer and 27,360 deaths attributable to
prostate cancer1. Studies show that prostate cancer prevalence is proportional to age2,
and can lead to ostesclerotic metastases . Additionally, African-American men and men
with a family history of prostate cancer are at increased risk for developing prostate
cancer and death due to their cancer1. The human prostate is a small walnut-sized
glandular male reproductive organ that is located below the urinary bladder and in front
of the rectum (Figure 1). There are three zones of the prostate (central, peripheral, and
transition), with each zone being responsible for the three main disorders of the prostate
in humans, namely prostatitis (infections), benign prostatic hyperplasia (BPH, organ
enlargement), and carcinoma (malignant tumors)4. The central zone makes up
approximately 25% of the prostatic glandular tissue, and is responsible for only 1-5% of
carcinomas. The peripheral zone is the largest zone, is where most cases of prostatitis
arise from, and up to 70% of carcinomas are located. Finally, the transitional zone is
responsible for BPH and roughly 20% of carcinomas4 (Figure 1). The American
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Figure 1. The prostate gland. There are three main zones of the prostate. The central
zone is responsible for 1-5% of carcinomas, and makes up approximately 25% of the
prostatic glandular tissue. The peripheral zone is the largest zone, is where most cases of
prostatitis arise from, and up to 70% of carcinomas are located. Finally, the transitional
zone is responsible for approximately 20% of carcinomas, and is the location for benign
prostatic hyperplasia.
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Urological Association (AUA) recommends for healthy men to start prostate cancer
screening at age 50 (or as early as 40 for high-risk populations), with screening tests
inclusive of a serum PSA test and a digital rectal exam (DRE). A PSA value above the
age-specific median (i.e. 0.7 ng/ml for 40 year old men), or an abnormal DRE (size,
contour, consistency) may prompt the clinician to recommend a prostatic biopsy. The
next course of action will be determined based on the biopsy results, which can include
watchful waiting/active surveillance, radical prostatectomy, radiation therapy, or
brachytherapy if the presence of localized tumors are detected5. The Gleason score is a
grading system which aids in determining the severity of a given prostate carcinoma.
This system is named after Dr. Donald F. Gleason, who developed the technique along
with other members of the Veterans Administration Cooperative Urological Research
Group (VACURG)6. The Gleason grading system relies solely on the cellular growth
patterns of prostate carcinomas, with a higher score indicating increasing cellular
differentiation. There are nine growth patterns, all of which the Gleason grading system
organizes into five histological grades6. From these five grades, a score between two and
ten is assigned to the tumor based on the sum of the primary and secondary grade patterns
(i.e. grade 3 + grade 4= Gleason score of 7). The primary grade represents the
predominant pattern present, while the secondary grade represents the second most
prevalent pattern6. It is imperative to know the two grades comprising the Gleason score,
as 4+3 is a more severe score of seven than 3+4. The Gleason score, along with a serum
PSA value and clinical staging of the tumor, allow for a clinician to assess a patient's
cancer as low, intermediate, or high risk (Table 1). With the abundant advances in
prostate cancer early detection, it has become evident that many cases involve clinically
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Table 1. Risk stratification schemes for prostate cancer prognosis
Prostate Cancer Risk

serum PSA value

Gleason Score

Clinical Stage

Natural History

Low Risk

<= lOng/ml

<=6

T l c o r T2a

Often indolent disease,
progression uncommon

Intermediate Risk

10to20ng/ml

7

T2b, but not qualifying
for high risk

Meaningful risk of
progression that is of
concern to most patients

High Risk

> 20 ng/ml

8 to 10

T2c

Significant risk of
progression

Current clinical practices use a combination of factors to determine the risk of prostate
cancer progression in men presenting with cancer-positive biopsies. A low risk
classification indicates that the cancer is not likely to progress to a more severe state;
with patients typically presenting with serum PSA values less than 10 ng/ml, a Gleason
score of less than 6, and a clinical staging of Tic or T2a. Classification of intermediate
risk is based on the patient presenting with a serum PSA value between 10 and 20 ng/ml,
a Gleason score of 7, or a clinical staging of T2b. These tumors have a moderate
potential of progressing to more aggressive disease, and treatment options should be
evaluated. Finally, prostate tumors classified as high risk will most likely progress to
aggressive disease, with patients presenting with a serum PSA value over 20 ng/ml, a
tumor Gleason score of 8 to 10, or a clinical staging of T2c. Table adapted from D'amico
et al., 1998 and Thompson et al., 2007.
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insignificant prostate carcinomas. This has lead to overdiagnosis of prostate cancer in
men, and comes along with various other complications that these men may not have
otherwise suffered from. The U.S. Preventative Services Task Force (USPSTF)
determined that treatment of prostate cancer due to screening protocols may lead to
erectile dysfunction, urinary incontinence, bowel dysfunction, and death7. In addition,
the USPSTF determined that the risks and benefits of prostate cancer screening in men
under 75 years of age cannot be assessed at this time, and that it is not recommended to
screen for prostate cancer in men over 75 years old7.

Prostate Specific Antigen as a Biomarker
Prostate specific antigen (PSA) is a 28.4 kDa glycoprotein that is secreted by the
prostatic epithelium. It is synthesized by both healthy and diseased prostate tissue8'9, and
its transcription is androgen-regulated10. It has a physiological role of liquefying seminal
fluid11'12, and is thought to do so by proteolytically digesting seminal fluid proteins such
as semenogelin-1 and -213. This kallikrein serine protease (hK3) was first described in
1966, further characterized in 1971 by Hara et al14, and first detected using a serum-based
test in 1980 by Pasidero et al15. PSA levels in seminal fluid are typically within the
range of 100-400 ug/ml, however they have been reported to be as high as 3 mg/ml16.
With tight regulation, it is common for only small amounts of PSA to leak into the blood
stream, leading to serum PSA concentrations to be normally 10-fold lower than PSA
levels in seminal fluid17. Previously, and as early as 1960, other groups had performed
various immunological studies and found multiple antigens specific to prostatic tissue18"
26

, some of which were later found to be similar to PSA27"29. Initial studies on "prostate-

specific antigens" were focused on finding markers for chronic prostatitis, infertility,
forensic purposes, contraception, and cancer . An immunoassay for the detection of
PSA for prostate cancer diagnoses was developed and refined by Chu et al. in the early
1980s30"32. Stamey et al. followed up these initial studies with a large study using a
significantly higher number of serum samples in 1987, finding that PSA serum levels
correlated with stages of prostate cancer as well as tumor volume, that PSA was a better
biomarker than the current clinical biomarker prostatic acid phosphatase (PAP), and that
PSA could also be used as a marker to monitor tumor response to radiation therapy33.
Clinically, serum PSA levels have been used as a diagnostic marker for prostate cancer,
with Myrtle et al.34 setting the threshold for serum PSA levels at 4.0 ng/ml in 1986, and
the U.S. FDA approving PSA as a marker to monitor patients being treated for prostate
cancer in the same year. PSA was not approved as a diagnostic prostate cancer
biomarker by the U.S. FDA until 1994. To date, PSA is the clinical biomarker routinely
measured in serum for detection of early prostate carcinomas33,35'36. However, it has
more recently been determined that the levels of PSA in serum do not efficiently
distinguish between non-cancerous prostatic pathologies, such as benign prostatic
hyperplasia (BPH) and prostatitis, and prostate cancer37"39. Outside of disease, other
factors such as age, body mass index (BMI), and race also affect serum PSA
concentrations40. Therefore, the PSA index, which is defined as free PSA (fPSA)
expressed as a percentage of total PSA (tPSA), has been used to improve PSA
specificity41. However, this value does not facilitate diagnosing prostate cancer in
patients with a serum PSA score of less than 10 ng/ml42, and additional studies report that
there is a 20.5% mean prostate cancer incidence where serum PSA levels were between
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2.5 and 4.0 ng/ml43. These discrepancies lead to many unnecessary tissue biopsies,
which in turn decrease patient quality of life, and therefore there is a pressing need to
improve the specificity of PSA as a biomarker, and continue to evaluate additional
biomarkers.

Prostatic Acid Phosphatase as a Biomarker
Prostatic acid phosphatase (PAP) is a 50 kDa dimeric glycoprotein which is found
in several human tissues such as platelets, lungs, osteoclasts, erythrocytes, liver and
kidney44'45, however it is present in 100-fold higher concentrations in human prostatic
tissue as compared to other organs46. As one of five functions by hydrolyzing organic
monophosphate esters47. A definitive physiological role of PAP within the reproductive
tract of men has yet to be established. PAP was the earliest biomarker for prostate
cancer, and is still used today in the clinic as a marker for metastatic prostate disease48'49.
PAP was first linked to prostatic tissue in 193534, and subsequently deemed a prostate
cancer biomarker for the next 50 years34'50. However, with the discovery of PSA and its
apparent organ specificity, PAP was quickly replaced in part due to the wide-spread
distribution of acid phosphatase isoenzymes throughout the human body33. The original
clinical assay for PAP assessed the levels of enzymatic activity in serum, yet early assays
were unable to determine if the activity detected was from prostate-derived PAP.
Various techniques were used to try to improve such assays, including the addition of Ltartrate to inhibit PAP derived directly from human prostatic tissues51, as well as the use
of thymolphthalein phosphate substrates52. However, these additions still could not
compete with the serum-based PSA test. Serum PAP's sensitivity was also criticized,
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and it was found that for early screening, PAP had a sensitivity of 45%, which paled in
comparison to a value of 96% sensitivity for PSA33. In addition to early screening, serum
PSA was also found to be a more sensitive marker than serum PAP for prostate cancer
staging53. In 1997, O'Dowd et al. declared that PAP was no longer useful in the clinical
staging of early prostate carcinomas54, which truly ended PAP's era as a prostate cancer
biomarker.

Additional Prostate Cancer Biomarker Candidates
In addition to PSA and PAP, other candidate molecules have also been examined
for their potential at diagnosing and staging prostate cancer. For example, prostate stem
cell antigen (PSCA) is a glycosylphosphatidylinositol-anchored cell surface antigen
located primarily in prostatic tissue and is thought to contribute to cellular proliferation
and signal transduction55. Elevated PSCA levels positively correlate with higher Gleason
grades in advanced prostate carcinomas, and is also potentially associated with androgenindependent prostate cancer56'57. However, most of these studies utilize prostate tissue,
with only one study which detected PSCA in peripheral blood samples58. Additionally, it
has yet to be determined if PSCA is a better diagnostic marker than PSA34. Prostatespecific membrane antigen (PSMA) is a type II integral membrane protein which is found
in the cytosol in normal prostate tissue and in the plasma membrane in prostate cancer
tissue59'60. PSMA has been studied extensively with results showing that protein serum
levels increase with prostate cancer and metastatic prostate cancer, and PSMA is
detectible in both serum and prostate tissue61"65. In addition, another study indicated that
PSMA levels are much higher in prostate cancer patients as compared to healthy patients

and patients with BPH . However, more studies are needed to confirm the clinical utility
of PSMA in early diagnosis of prostate carcinomas34. Transmembrane protease serine 2
(TMPRSS2) is a transmembrane serine protease which is expressed primarily in prostate
tissue67. In situ hybridization and microarray studies have shown that TMPRSS2
expression is androgen regulated, and that TMPRSS2 is expressed in normal and
cancerous prostate basal cells, unlike other serine proteases, like PSA, which are found in
the prostate secretory cells67. This indicates the role TMPRSS2 may play in a smaller
subset of prostate carcinomas, allowing for an additional and alternative route of prostate
cancer diagnosis. Prostasin is another membrane-bound serine protease, which while it is
expressed in most human tissues; its expression is highest in prostate tissue68. The
soluble form of prostasin is easily purified from seminal fluid68, and is N-linked
glycosylated69, indicating its utility as a prostate cancer biomarker target. These
candidate biomarkers are all localized to the cell surface and some are found in a secreted
form as well, demonstrating their potential role in prostate carcinoma, as well as making
them easier targets than intercellular molecules. Two additional candidate markers for
prostate cancer, 73-kDa type II Golgi membrane antigen (GP73; GOLPH2) and amethyl-Co-racemase (AMACR) are not localized to the cell surface; however they have
been shown to be tissue-specific, and have proven to still be reliable markers. GP73 is a
Golgi phosphoprotein which has previously been shown to be a useful serum marker for
hepatocellular carcinoma70"73. More recently, GP73 mRNA transcripts found in human
sedimented urine samples have shown effectiveness in diagnosing early prostate
carcinomas74. Additionally, it has been shown to be upregulated in prostate cancer
tissues as compared to normal, healthy prostate tissues75, showing its value as a prostate
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cancer biomarker. Finally, AMACR is primarily localized to the peroxisomes and
mitochondria within prostatic tissues, and has been found to be overexpressed in prostate
carcinoma tissues76"78. Its clinically utility has been shown by the relatively high
sensitivity and specificity AMACR has for diagnosing prostate cancer79. Furthermore,
genomic and single nucleotide polymorphism (SNP) studies of AMACR have indicated a
role this gene plays in both early prostate carcinomas and familial prostate cancer80"82.
Overall, there are many candidate markers for the early diagnosis and prognosis of
prostate cancer; however, none of these markers, like PSA and PAP, have yet to aid in
decreasing the number of unnecessary biopsies and radical prostatectomies that still
afflict many men today.

1.2 Protein Glycosylation
Subcellular molecules located both inside and outside the cell and containing
carbohydrate components are called glycoconjugates, namely glycoproteins, glycolipids,
proteoglycans, and glycosaminoglycans. Protein glycosylation is a common posttranslational modification which has proven to be a useful disease marker83'84, with many
studies outlining altered glycosylation patterns in cancerous samples as compared to
normal healthy samples85'86. Protein glycosylation has long been shown to be altered in
cancerous tissues as compared to normal tissues, suggesting that characterization of this
type of post-translational modification could lead to more specific biomarkers in the
clinic. Proteins become glycosylated in both the endoplasmic reticulum (ER) and the
Golgi apparatus (Golgi), where post-translational processing occurs prior to transport.
Fully processed glycoproteins are most commonly found in lysosomes, attached to the
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outside of the cell surface, and in the extracellular matrix; however there have been
several examples of both nuclear and cytoplasmic glycosylation87"91, all of which seem to
be an addition of a single monosaccharide, unlike the complex oligosaccharide structures
seen on other glycoproteins91. There are two main types of glycosylation of proteins as
they are processed in the ER and Golgi: O-linked and N-linked (Figure 2).

O-linked Glycosylation
O-linked glycosylation occurs in the Golgi apparatus and involves the attachment
of monosaccharide residues to the hydroxyl group of either serine or threonine in a
sequential manner. This is achieved by glycosyltransferases present in the Golgi. These
carbohydrate chains are typically 1-4 units long, and most commonly begin with the
addition of N-acetylgalactosamine to the protein (Figure 2). Therefore most often Oglycans refer to the O-GalNAc linkage, although O-GlcNAc and O-mannose are
alternative linkages. The most common examples of an O-linked glycoprotein are
mucins, which are a class of secreted and plasma membrane glycoproteins having several
clusters of O-linked glycans. These proteins contain regions rich in serine, threonine and
proline residues.

N-linked glycosylation
N-linked glycosylation is achieved through a more complex process than O-linked
modifications and results in three main classes of N-linked oligosaccharides: 1) highmannose-type, 2) complex-type, and 3) hybrid-type (Figure 3). A preformed 14carbohydrate oligosaccharide which is attached to a dolichol donor is a structure common
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Figure 2. Example oligosaccharide structures of O- and N-linked protein
glycosylation. O-GalNAc is the most commonly observed O-linkage to serine or
threonine residues on proteins. This representative complex O-GalNAc glycoform can be
found attached to human respiratory mucins. The most basic O-GalNAc core structure is
observed linked to a single galactose residue, however it can be extended, branched, and
terminated by fucose in various linkages, sialic acid in a2-3 linkage, or sialic acid a2-6linked to the core GalNAc. N-linked oligosaccharides are typically more complex
structures as compared to O-linked oligosaccharides, with extensive branching and
extension off of the universal pentasaccharide core. Adapted from Varki et al, 2009.
Cartoon representations are as follows: • =GlcNAc, O =Mannose, O =Galactose, A
=Fucose, ^=NeuAc, D=GalNAc
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Figure 3. N-linked oligosaccharide subtypes. There are 3 distinct subtypes of Nlinked glycans, each based on the type of monosaccharides present in the oligosaccharide
branching chains. High-mannose structures consist of the core structure plus any number
of mannose monosaccharides decorating the terminal branches. Complex subtypes
consist of the core pentasaccharide with any number of monosaccharides and various
branching patterns. These structures are usually decorated with a combination of Nacetylglucosamine, N-acetylgalactosamine, galactose, sialic acid and fucose
monosaccharides. It is also common to see the core N-acetylglucosamine bound by a
"core" fiicose. Finally, the hybrid subtypes are classified by having one main arm
resembling a high-mannose structure, while the other arm resembles a complex structure,
therefore being termed a "hybrid" of these two different subtypes. Cartoon
representations are as follows: • =GlcNAc, O =Mannose, O =Galactose, A=Fucose,
•=NeuAc, D=GalNAc
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to most eukaryotic cells. This compound consists of three glucose, nine mannose, and
two N-acetylglucosamine molecules and is attached to dolichol by a pyrophosphoryl
residue. Dolichol is a long-chained polyisoprenoid lipid embedded in the ER membrane.
The carbohydrate residues are added in a concerted manner by specific enzymes. This
process begins on the cytosolic face of the ER with the addition of the two GlcNAc and
five mannose residues in a sequential manner. At this point, the structure "flips" so that it
is now on the lumenal face of the ER. The next seven carbohydrates (four mannoses and
three glucoses) are added one at a time from a nucleotide-sugar donor (UDP) to a
dolichol molecule embedded on the cytosolic face of the ER. The dolichol-sugar moiety
then flips to the lumen face and each monosaccharide is transferred to the growing sugar
chain. As a protein is being elongated co-translationally into the ER lumen, an N-linked
glycosylation site will be recognized and the 14-mer oligosaccharide is transferred to the
nascent protein chain by an enzyme called oligosaccharyl transferase. The
oligosaccharide is covalently attached to the amide nitrogen of asparagine residues that
are followed by any amino acid except proline, followed by either a serine or threonine
(N-X-S/T). This tripeptide sequence is recognized and triggers the transfer of the
oligosaccharide from dolichol to the protein en bloc. However, only about thirty percent
of these sites end up being occupied, with the remaining sites believed to be blocked by
the protein folding process which is occurring at the same time92. Immediately, the three
glucose residues and one mannose residue are removed, each by a different glycosidase.
It is thought that the glucose residues serve as a signal to indicate that the oligosaccharide
is ready for transfer to the protein as well as to indicate that the protein has achieved
proper folding and is ready for transport to the cis Golgi92. The glycoprotein will be
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further processed in the ER and Golgi apparatus; however the pentasaccharide "core" of
two GlcNAc and 3 mannose residues is common to all N-linked glycans. The
glycopeptide will then be transported to the cis Golgi where it will be further modified.
For example, secretory or plasma membrane proteins will lose an additional three
mannose residues. Typically while in the medial Golgi, two more mannoses are
removed, followed by the addition of two GlcNAc and one fucose residues. Finally, the
glycoprotein will receive one GlcNAc, one galactose, and one sialic acid while in the
trans Golgi92. The complexity and structure of N-linked carbohydrates is determined
both by the sequence and conformation of the protein itself as well as the type of
glycosyltransferases present in the Golgi during the glycosylation process. N-linked
glycans are typically branched and can be highly decorated. By the time the protein
reaches the trans Golgi, it will be completely modified and ready for transport. In disease
states, it is believed that the great biodiversity of both glycosyltransferases and
glycosidases present in the vertebrate Golgi are responsible for alteration of "normal"
glycosylation patterns92.

The Carbohydrate-Cancer Connection
Cancer progression has several stages including proliferation, invasion,
angiogenesis, metastasis, and immunity; all of which may be affected by a number of
glycoconjugates as indicated by innumerous published studies ' " . The first stage,
tumor proliferation, begins with the deregulation of the cell cycle by a disruption in the
balance of tumor suppressors and oncogenes. Correlations between tumor proliferation
and carbohydrates have been difficult to determine, however it seems that glycoproteins
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and glycolipids most commonly play a role in this stage of cancer progression. For
example, N-linked glycosylation of the insulin-like growth factor 1 receptor (IGF1R) has
been shown to necessitate the phosphorylation and translocation of IGF1R, therefore
leading to growth and survival of melanoma and sarcoma cells96. In addition, extensive
studies have shown the role of mucins and other O-linked glycans in the role of tumor
proliferation97"99. The mucin MUC4 gene has been shown to be over-expressed on the
surface of mammary tumor cells as compared to normal mammary epithelium100. MUC4
is responsible for the up-regulation of the epidermal growth factor (EGF) receptor
ERBB2, which then aids in the inhibition of apoptosis, a common occurrence in tumor
proliferation .
After tumor cells begin to proliferate and the tumor continues to grow, the
peripheral cells then begin to detach from each other and from the extracellular matrix,
where they then invade and migrate through adjacent tissue. This invasion process
requires many factors, including the alteration of cell-surface receptors and their ligands,
as well as proteases and glycosidases to degrade the extracellular matrix. These changes
require the aid of glycoconjugates such as N-linked and O-linked glycoproteins, and
proteoglycans. For example, increased sialylation has been shown to play a vital role in
tumor invasion, likely due to the highly negative nature of sialylated glycoforms which
may aid in the cellular detachment stage93'101. Once tumor cells begin to rapidly grow
and spread, they need additional nutrients and therefore must create their own vasculature
to supply such nutrients, a process known as tumor angiogenesis. Heparan sulfate
proteoglycans are the most commonly seen glycoconjugates involved in tumor
angiogenesis. Certain pro-angiogenic factors, such as vascular epithelial growth factor
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(VEGF), interleukin-8 (IL-8), and platelet-derived growth factor (PDGF) to name a few,
bind heparan sulfate102, indicating a correlation between these proteoglycans and tumor
angiogenesis.
The next stage in cancer progression involves the movement of tumor aggregates
to distant organs, also known as metastasis. Selectins are cell-surface receptors
responsible for cell-cell adhesions which are involved in tumor metastasis. Their ligands
often carry O-linked oligosaccharides decorated with sialic acid, fucose, and sulfate92'93.
Examples of these ligands are the Lewis type blood group antigens, specifically sialyl
Lewis X (SLex) and sialyl Lewis A (SLeA), which are shown to be over-expressed on
tumor cells as compared to their normal cellular counterparts for lung, colon, gastric, and
pancreatic cancers93'103"105. CA19-9 is a sialyl Lewis A serum tumor biomarker which is
used to detect many gastrointestinal cancers. However, there are many false positives
using this serum test, as CA19-9 will sometimes also recognize certain inflammatory
states of the aforementioned tissues . Specific to prostate cancer, cancerous cells have a
tendency to metastasize to bone, and it is thought that E-selectin with the aid of sialyl
Lewis X is responsible for the binding of circulating prostate tumor cells to the bone
marrow endothelial cells107. The final stages of cancer progression involve the alteration
of host immunity, which allows the tumor to continue to grow and spread throughout the
host organism. While little is known about the role of glycosylation in this final stage,
some studies have shown that certain glycosphingolipids and O-linked glycoproteins may
be involved in immune silencing, allowing the tumor to evade the cytotoxic effects of the
host immune system93,108.
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Due to the widely-seen involvement of glycosylation in various cancer systems, it
is likely that altered glycosylation states are involved in prostate cancer progression as
well, and that these changes can be detected by mass spectrometry-based strategies. A
few reports have shown that the overexpression of O-glycosylated mucins are involved in
prostate cancer progression109"111, while others have associated altered N-glycosylation
patterns with prostate cancer, either globally112, or protein-specifically113,114. In
particular, the glycosylation of PSMA was studied in prostate cancer tissues, serum, and
metastatic cell lines (LNCaP), indicating the presence of complex N-linked glycans on in
vivo sources of PSMA, and high mannose N-glycans on PSMA from immortalized cell
lines113.

PSA glycosylation
Previous studies on PSA glycosylation have compared seminal plasma from
healthy donors to prostate tumor metastatic cell line LNCaP115"117, as well as normal
seminal plasma to prostate cancer and BPH sera118. PSA contains 8% carbohydrates by
mass119, and has one glycosylation site at asparagine (Asn)-45120. The structure of this
glycan has been previously reported to be of either high-mannose subtype121 or a
complex sub-type with frequent sialylation, core fucosylation, and a number of terminal
N-acetylgalactosamines (GalNAc) when purified from healthy seminal plasma
samples117. PSA glycans isolated from LNCaP cell lines have also been characterized as
having some triantennary structures116, as well as decreased sialic acid content and the
presence of increased fucose and GalNAc content115. Because of advances in the PSA
serum test which include the comparison of different forms of PSA, a recent study was
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completed that monitored the presence of sialic acid monosaccharides on free and
proPSA in serum, seminal plasma and tissues from both healthy and prostate cancer
patients122. This study did not detect any significant differences in sialylation among the
different groups or sample sets122. A second study compared free and complexed PSA
glycans derived from serum, concluding that the glycans from both forms of PSA were
primarily sialylated and fucosylated biantennary structures123. Although less prevalent,
the presence of a few multiantennary complex structures were detected as well123.
However, for the aforementioned studies, the specific composition and anomeric
structural configurations for each oligosaccharide isolated were not determined, and these
studies involved analysis of samples obtained from very few clinical samples.

PAP glycosylation
PAP has three glycosylation sites at Asn-62, Asn-188, and Asn-301124'125, making
it a more difficult target for site specific structural characterization, yet one that may be a
suitable complement to PSA. Earlier X-ray crystallography of PAP from normal seminal
plasma has found the Asn-62 and Asn-301 glycan modifications consisted of primarily
high mannose oligosaccharides, while glycans at Asn-188 had more complex structures
containing sialic acid and fucose124. In relation to cancer, one study involving lectin
analysis of PAP derived from tissue in BPH and prostate cancer patients found evidence
of a decrease in the high mannose chains of Asn-62 and Asn-301, as well as an increase
1 2S

of non-fucosylated hybrid structures in prostate cancer as compared to BPH . Similar
to the studies on PSA glycosylation, these studies on PAP oligosaccharide content lack in
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detailed structural information, and include low numbers of clinical samples used for
each study.

1.3 Proximal Fluids of the Prostate for Biomarker Discovery
Proximal fluids are defined as any fluid found adjacent to a given tissue. It is
currently understood that proximal fluids are a great source for biomarker discovery126,
with seminal plasma and expressed-prostatic secretion (EPS) fluids both being proximal
to the prostate. In addition, PSA and PAP protein concentrations are much higher in both
seminal plasma and EPS fluids relative to blood127, allowing for enhanced purification,
detection, and analysis of these biomarkers. Seminal plasma consists of fluids originating
not only from the prostate, but also from several other male accessory glands such as the
seminal vesicles, epididymis, and Cowper's gland128. Seminal fluid has been used in
research and the clinic for many purposes outside of the cancer realm, and has also been
analyzed in several studies for biomarker purposes related to both prostate and testicular
cancers128"130. Clinically, the term "expressed" is used to describe the process of
manually squeezing a gland, which results in fluid being expelled and subsequently
collected. EPS represents the fluid being secreted by the prostate following a prostate
massage, which in turn is excreted via the urethra alone or with urine. This fluid is
commonly collected in the clinic to examine chronic prostatitis and inflammatory chronic
pelvic pain syndrome131. In addition, the cellular sediment obtained from EPS fluids is
currently being used for prostate cell-associated PCA3 mRNA testing (Gen-Probe Inc,
San Diego, CA). These studies aim to develop a genetic based clinical assay by using the
mRNA levels of PCA3 as a marker for prostate cancer74'132134. Using these EPS fluids
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for protein-based biomarker discovery or in the clinic for biomarker screening has yet to
gain popularity. Because these fluids should be enriched for prostatic proteins that may
be difficult to detect in serum, it seems likely that they have high utility in the clinic for
the screening and potential staging of prostate cancer.

1.4 Proteomics, Glycomics and the Advances of Mass Spectrometry
With the completion of the Human Genome Project in 2001135, researchers began
focusing on the next level of discovery, that of the human proteome as well as proteomes
of many other species. The term "proteome" was first coined in 1994136 and was initially
defined as the protein complement to the genome, with "proteomics" being defined as the
study of protein structure and function in a specific sample (i.e. tissue, cell, or bodily
fluid) at a specific time. While the human genome is complex, the complementing
proteome contains even more information, due to the fact that individual genes can give
rise to many different proteins and isoforms of a protein. These protein profiles may be
altered due to the physiological and pathological states at a given time in a given subject,
and commonly, post-translational modifications are responsible for differing disease
phenotypes137. Due to these factors, it is possible to detect a protein-based biomarker that
can differentiate between healthy and diseased states for many conditions, including
cancer.

Two-Dimensional Electrophoresis
Two-dimensional electrophoresis (2DE) was and is still used today for initial
sample separation for proteomics analyses. This separation methodology as applied to
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proteins relies on two independent parameters that are functional properties of all
proteins: 1) their molecular mass and 2) their isoelectric point (pi), the pH at which the
net charge of each protein is zero. The pi of a protein is a property unique to each protein
dependent on the total number of positively and negatively charged constituent amino
acids. At a pH above the pi, a protein carries a net negative charge, and at a pH below
the pi, a protein carries a net positive charge. These same properties also allow 2DE to
separate proteins based on their post-translational modifications (i.e. glycosylation),
particularly if these modifications are charged or have substantial mass. For most
applications, the first dimension for 2DE is an isoelectrofocusing (IEF) step, followed by
a conventional sodium dodecyl sulfate (SDS)-polyacrylamide gel separation based on
molecular mass in the second dimension. The fundamental aspects of the most
commonly used approaches of 2DE for protein separations were reported independently
by Klose138 and O'Farrell139 in 1975. Original innovations in isoelectric focusing relied
on the inclusion of multi-charged chemicals termed ampholytes, that when placed in an
electric field would generate and align the ampholyte molecules into a pH gradient.
Originally, this was accomplished by combining the ampholytes with acrylamide, and
then polymerizing these solutions in glass tubes (referred to commonly as "tube gels").
While this was an effective way to perform IEF separations of proteins, the method
required specialized equipment and was difficult to reproduce gel to gel. A major
improvement in IEF was originally reported in 1982 by Bjellqvist et al.140, who reported
the creation of immobilized pH gradient (IPG) strips. Ampholyte molecules were
replaced by acidic and basic acrylamido derivatives that are co-formed with acrylamide
gel polymerization on plastic backed strips; hence, the tube gels have been replaced by
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these IPG plastic strips. These improvements in the IEF component of 2DE have driven
increased use of this approach in proteomics. It is necessary to keep in consideration how
the samples will be analyzed post-2DE. Protease inhibitors play an important role in
maintaining the integrity of a sample's proteome; however some, such as
phenylmethylsulfonyl fluoride (PMSF), can interfere with downstream analysis, such as
tryptic digestion. Depending on the complexity of the sample(s) being analyzed, there
may be too many spots to effectively compare and analyze with the human eye. Thus,
there are various analysis programs available that can compare spots between gels. These
programs are based on manually selecting a certain number of consistent landmarks
between the gels to be analyzed, from which the software can then align the gels and
determine any differential spots. Consequently, the most critical step of these analyses is
spot detection and quantification. Alternatively, 2D gels can be transferred to a
membrane such as PVDF for immunoblotting. At this point, proteins of interest can be
detected by following a standard western blotting protocol, making this method useful
when wanting to quickly visualize the possible multiple isoforms of one protein.

Development of Protein Sequencing Methods
After a decade of study, insulin was the first protein to be completely structurally
characterized in 1954. This mammoth task was achieved by Frederick Sanger and his
colleagues using a method termed the dinitrophenyl group-labeling (DNP) method, which
covalently modifies the terminal amino acid in a peptide141. This DNP group gives the
peptide a distinctive yellow color which allows for visualization using two-dimensional
paper chromatography. In addition, the DNP group makes the derivatized amino acid
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resistant to acid hydrolysis. In order to get a contiguous sequence, the sample was first
fully hydrolyzed, and then sequential partial hydrolysis reactions were performed,
allowing for larger and larger peptide fragments with overlapping sequence information.
In concert with the DNP labeling method, partition (filter paper) chromatography,
developed by AJ.P. Martin and R.L.M. Synge in 1952, allows for the separation of the
amino acids and peptides and was the basis for modern chromatography separation
techniques142.
The year 1930 saw the first successful stepwise degradation of peptides
performed by Abderhalden and Brockmann using phenylisocyanate (PIC)143. However, it
wasn't until Pehr Victor Edman altered the method and begun using pheylisothiocyanate
(PITC) as a coupling reagent that the method gained popularity. The change in the
reagent allowed for a more easily cleaved labeled amino acid, therefore allowing for
more successful analysis. Today's amino-terminal sequencing methods are all based on
the Edman degradation procedure144. Edman degradation comprises of three steps. The
first step is the coupling reaction where the free amino-terminal amino acid is labeled
with PITC which forms a phenylthiocarbamyl (PTC) polypeptide. It is noteworthy that
polypeptides that are modified at the amino terminal cannot be coupled with the PITC.
The second step involves cleavage of the PTC-amino acid by acid hydrolysis creating an
anilinothiazolinone (ATZ) amino acid. This step also results in a shortened polypeptide
which can then be used for subsequent coupling and cleavage in repetitive cycles. The
third and final step of Edman degradation involves conversion of the unstable ATZ
amino acid into a more stable phenylthiohydrantoin (PTH) derivative. Finally the
derivatized amino acids are sequentially identified using HPLC. Automation of this
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procedure was first performed in 1967 which automated the coupling and cleavage steps
and allowed researchers to routinely identify the sequence of the first 30-40 amino acids
• 145 146

in a given protein '

History of Mass Spectrometry
While the Edman degradation method has been revamped and utilized for many years,
the advances in mass spectrometry have almost but all replaced this protein sequencing
method. Mass spectrometry based techniques are much more sensitive, can handle
complex protein mixtures, and can be used in a more high-throughput manner. The idea
of mass spectrometry dates back to 1897 when J.J. Thomson discovered electrons using
cathode rays. He observed that the ions in the gaseous phase moved through the cathode
ray tubes in a trajectory that were proportional to their "mass-to-charge" (m/z) ratios142.
Based on his discovery, the first mass spectrometer called a parabola spectrograph was
conceived. Over the decades more sophisticated instruments were developed. The first
time-of-flight (TOF) analyzer was developed in 1946 by W.F. Stephens, with Wolfgang
Paul creating the first quadrupole mass analyzer in the mid 1950's. Paul also created the
first quadrupole ion trap, and the ion trap first became available commercially in 1983147.
Currently, TOF, quadrupole, and quadrupole ion trap technologies are the most widely
used mass analyzers in mass spectrometry laboratories147. All mass spectrometers have
four basic components: an ionization source, a mass analyzer, a mass detector, and a data
processor (Figure 4). The ionization source is responsible for converting the analytes
from either their solid or liquid states into gaseous-phase ions. These ions are then
transferred to the mass analyzer where they will be separated by either electric or
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Figure 4. Components of a mass spectrometer. After the sample is introduced to the
ionization source, the analytes are converted from either their solid or liquid states into
gaseous-phase ions by the ionization source. The mass analyzer will then separate the
ions by either electric or magnetic fields. The ions will then strike the detector
individually based on their m/z value as they leave the mass analyzer. Finally, the data
processor supplies the visual output of analyte information, showing both the m/z value
and the relative abundance of each ion measured by the detector. Adapted from Simpson,
2003.
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magnetic fields, which are commonly observed as a function of time. After traveling
through the mass analyzer, the ions will strike the detector one at a time, based on their
m/z value. The data processor is responsible for the visual output of analyte information,
indicating both the m/z value and the relative abundance of each ion measured by the
detector142.

Soft Ionization Mass Spectrometry
Fast atom bombardment ionization (FAB) was developed in the early 1980s148'149
and was the first soft-ionization mass spectrometry technique available for use with
proteins and peptides142. This technology works by dissolving the analyte (i.e. protein or
peptide) in a nonvolatile liquid matrix (i.e. glycerol), which is then placed under vacuum
in the instrument. Next, the sample-matrix mixture will be bombarded with a flow of
fast-moving neutral atoms. These atoms usually derive from ionization of argon, and are
used to change the analyte ions into a gaseous phase. This method allows for the analysis
of ions that are 10,000 daltons or greater. Thus, this method is not optimal for small
peptide fragments, or other small biochemical molecules.
For some instruments, a matrix is needed to help the analyte (sample) ionize and
travel to the mass detector. Matrix-assisted laser desorption/ionization (MALDI) begins
with the mixture of matrix and analyte. MALDI was first developed in 1988 by Karas
and Hillenkamp150. Matrices are acidic compounds which can be absorbed at different
laser wavelengths, usually UV337nm- The matrix is typically applied to the analyte in
1000-fold concentration142. For glycopeptide and glycan analyses, typically 2,5dihydroxybenzoic acid (2,5-DHB) is used, as it is best at stabilizing the sialic acids on
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acidic glycans. The analyte-matrix mixture is then applied as a few microliters to a target
plate, where the plate itself can have different chemistries. The sample and matrix are
allowed to co-crystallize prior to entering the instrument. Energy in the form of a pulsed
UV laser is applied to the spot with the crystallized sample-matrix. The ions will excite
and be desorbed from the solid matrix mixture and the matrix helps stabilize the singlycharged ions as they travel through a strong electric field, then through the TOF, and
finally to the mass detector. The TOF mass analyzer will measure the m/z values of the
analytes, which is calculated based on the time it takes for a specific ion to travel a set
distance and strike the detector142.
Another soft-ionization technology termed electrospray ionization (ESI) was first
developed in 1989 by Fenn et al151. Samples in a liquid phase (typically organic) are hit
with a high-voltage potential as they are passed through a small capillary tube. The ions
are then desorbed into the gaseous phase and rapidly evaporate into charged droplets.
This process occurs due to both high heat and a strong electric field present at the tip of
the capillary tube. From here, the samples will enter the mass analyzer, which is
typically either an ion trap or a quadrupole. Unique to ESI, singly and multiply charged
ions can arise from a single precursor ion as they travel out of the capillary and to the
mass analyzer. This feature allows larger molecules (> 10,000 daltons) to be accurately
evaluated by a mass analyzer such as the quadrupole or ion trap which typically have a
limit of detection of 10,000 daltons. The number of charges an ion may carry as it
evaporates off of the capillary is dependent on factors such as the voltage potential, the
solvent pH and composition, and the analyte itself142. Fortunately, a high-resolving
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instrument is capable of determining the charge state in addition to the mass of a given
ion, providing the user with even more valuable data.

Tandem Mass Spectrometry and Liquid Chromatography Coupled to Tandem
Mass Spectrometry
As a mass spectrometer first scans and detects the ions coming from the analyte,
these initial spectra are full MS scans, representing parent ions. These intact parent ions
can provide information all on their own, however even more information can be
obtained by fragmentation of the parent ions. This secondary analysis is referred to as
tandem MS, MS/MS, or MS". Fragmentation studies will offer structural information of
the compound being analyzed. Most commercially available mass spectrometers using
soft ionization are capable of tandem MS. A precursor (parent) ion is selected from the
initial stage of analysis, an intermediate reaction event occurs, the resulting "product
ions" are analyzed142. In the case of MS", these secondary stages are repeated
consecutively on individual ion peaks until all information desired has been obtained.
The intermediate reaction events are where the precursor ions are fragmented into
product ions. These events require a source of high energy which varies based on the
type of instrument being used, as well as the type of analyte being fragmented. The most
common form of energy used is collision-induced dissociation (CID), which involves the
use of an inert gas (i.e. helium or argon) to excite the ions and cause them to break apart.
There are two categories of tandem mass spectrometers. The first involves a
tandem-in-space instrument which has multiple mass analyzers in tandem, each
responsible for a specific set of analyses142. Examples of such instruments include
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MALDI-TOF/TOF, triple quadrupole instruments, and hybrid mass spectrometers. The
second category includes a tandem-in-time instrument that has only one mass analyzer,
allowing for the tandem analyses to take place in the same analyzer; however the events
are separated in time142. Examples of these types of tandem instruments include
quadrupole ion trap analyzers coupled with either MALDI or ESI, and Fourier transformion cyclotron resonance (FT-ICR).
Numerous mass spectrometer instruments today work in conjunction with liquid
chromatography (LC) systems, and these types of systems are commonly referred to as
LC-MS/MS. These on-line systems allow for analyte separation prior to entry into the
mass spectrometer, thus allowing for more in-depth analyses of a given sample. They
also allow for gel-independent separation of highly complex peptide mixtures, which was
first demonstrated by Hunt et al. in 1992136'152. Most of these separations are achieved
using reversed-phase high-performance liquid chromatography (RP-HPLC) coupled to
ESI. This separation allows for complex mixtures to be applied to a mass spectrometer
(i.e. seminal plasma or EPS fluids) without losing any protein or peptide information. To
further improve the sensitivity of the MS/MS analysis, capillary columns can be utilized
with this type of LC being referred to as nano-LC. These differ from traditional HPLC
columns by being narrower, therefore slowing down the flow rate and also by functioning
as the ionization source (i.e. nanospray ionization or NSI). This will also further
concentrate the sample before it is sprayed into the mass spectrometer142.

Protein Identification by Mass Spectrometry
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The emergence of protein databases began in the late 1970's and early 1980's as a
1 S^

result of the effectiveness of 2-DE protein profiles

. Computer software programs

capable of subtractive pattern analysis, clustering algorithms, and multivariate statistics
were developed to complement these databases, allowing for further characterization of
proteins isolated by 2-DE136,154"157. These early databases and software programs were
never fully implemented due to the complexity of 2-DE analysis, as well as the growing
popularity of soft ionization techniques in the late 1980's, causing for a surge of protein
identification methods based on mass spectrometer analysis in the early 1990's136'158.
Two main methods came from this decade: peptide mass finger printing (PMF) and
tandem mass spectrometry. The first, PMF, is also known as peptide mapping or peptide
mass mapping, and relies on a list of experimental peptide masses matching up to the
calculated list of all peptide masses of a each protein entry in a given database, thus
resulting in protein identification136. Five groups separately, yet nearly concurrently,
developed computer software capable of protein identification by PMF159"163. The PMF
method is regularly used to identify gel-separated proteins, and almost universally used in
conjunction with MALDI-TOF mass spectrometers136. The second protein identification
method utilizes tandem mass spectrometry by analyzing the fragmentation spectra and
comparing it against a given database search engine using a mathematical algorithm, such
as SEQUEST164 or MASCOT, which can also be used for PMF searches165. These two
protein identification methods are still the most widely used today in proteomic studies
today. The abovementioned search engines are used in conjunction with publically
available sequence databases. Both protein sequence databases164'166, as well as the
human genome library135'167 have been established, with new protein sequences
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constantly being added, thus allowing for on-going improvement to the accuracy of
peptide searches.

Carbohydrate Structural Analysis by Mass Spectrometry
In 1988, Rademacher, Parekh, and Dwek first coined the term "glycobiology",
with the intention for the term to highlight the marriage of traditional carbohydrate
chemistry and biochemistry disciplines to the modern cellular and molecular biology
disciplines of glycans92. Today, the study of oligosaccharide, or glycan, structure and
function can also be identified as glycomics. The term glycan is used to describe a chain
of sugars, whether they be linear or branched.
Historically, structural N-glycan analysis is performed with the use of
exoglycosidases and gelfiltrationchromatography, HPLC, or MALDI-MS168. Full
characterization of a given glycan molecule entails analysis of monosaccharide
composition, sequence, branching, linkage, and anomericity of said glycan169. However,
obtaining all of the above information is difficult and tedious. The use of
exoglycosidases and tandem MS are what allow for the elucidation of glycan structure
and linkage. Exoglycosidases are enzymes with specificity for certain monosaccharides
and in some cases, certain glycosidic bonds. For example, neuraminidase will only
remove terminal sialic acids. The loss of the monosaccharide from the entire moiety is
then monitored by the abovementioned methods. This stepwise process may be tedious
and requires the availability of a wide range of exoglycosidases; however the end result is
a complete structural determination of the glycan of interest. While this protocol was
traditionally only applied to N-glycan analysis, it is commonly used for O-glycan
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analysis as well170. Most recently, the advances in mass spectrometers have allowed
researchers to bypass the exoglycosidase steps and rely solely on MS/MS fragmentation
data to analyze N-glycan structural information. Fast atom bombardment (FAB) mass
spectrometry was the forefather in this type of analysis, but has been replaced by more
sensitive technologies like ESI or MALDI ionization168.
A second aspect of glycan analysis requires the cleavage of the intact
oligosaccharide from the protein or peptide, which can be achieved by either chemical or
enzymatic reactions. The chemical method typically relies on hydrazine, which will
destroy any protein or peptide information, however it quickly and easily results in a
cleaved glycan prepared for further analysis. Endoglycosidases are enzymes which will
cleave N-linked oligosaccharides from proteins and peptides, and include two different
types of cleavage. Enzymes such as Endo F and Endo H (both favor cleavage of high171

mannose types) , and Endo D (cleavage of complex glycans)
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cleave between the two

core GlcNAc residues, therefore leaving the first GlcNAc residue attached to the
protein . Alternatively, PNGase A (purified from almonds, cleaves both high-mannose
and complex glycans)172 and PNGase F remove the entire oligosaccharide cleaving
between the first GlcNAc and the asparagine residues, and as a result, these enzymes are
termed peptide ./V-glycosidases. The most popular enzyme today for removing an entire
N-linked glycan from the protein is PNGase F (Peptide-N4-(acetyl-6-glucosaminyl)asparagine amidase)173. PNGase F gained its popularity because it is capable of
hydrolyzing all types of N-glycans, including high-mannose, hybrid, and bi-, tri-, and
tetraantennary structures in a rapid manner173. PNGase F is purified from
Flavobacterium meningosepticum, and recognizes the tripeptide N-glycosylation signal,
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cleaving the covalent linkage between the asparagine residue and the first GlcNAc; as
long as there is not a core a-(l-3)-linked fucose present. This modification doesn't seem
to present a problem with mammalian-derived samples whose N-linked glycopeptides
carry core fucoses with an a-(l-6) linkage. In addition to the removal of the intact Nglycan by PNGase F, the enzymatic cleavage reaction results in conversion of the
asparagine residue to an aspartic acid residue. This alteration allows for additional
analysis of the peptide portion of the glycopeptide. N-linked glycosylation sites that are
truly occupied can be identified by first incubating a peptide mixture with PNGase F
followed by capture of the deglycosylated peptides and mass spectrometry analysis of the
peptides by either MALDI or ESI and a protein database search specific for the
deamidation modification (one dalton mass difference) to the peptide174. The resultant
intact N-glycans from PNGase F digestions can be analyzed directly by mass
spectrometry, or they can first be derivatized by either the addition of afluorescentlabel
(i.e. 2-Aminobenzoic acid, 2-AA; 2-Aminobenzamide, 2-AB) or by chemical
modification (i.e. permethylation). Underivatized glycans are less stable and therefore
more likely to fragment in full MS scans, thus complicating the subsequent structural
analysis.
Glycopeptide analysis is widely used today in glycomic studies; however the
properties of glycosylated peptides pose problems in mass spectrometry analyses. The
two main issues are due to the fact that protein glycosylation is very heterogeneous, and
that glycopeptides typically do not ionize as well as their nonglycosylated counterparts,
and therefore these peaks are often suppressed. Despite these complications, both
MALDI and ESI soft ionization techniques are capable of analyzing the carbohydrate
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structures attached to the peptides, especially when used in a tandem mass spectrometry
mode. MALDI is more commonly used for glycan identification and structural
determination, while ESI is better at obtaining more detailed structural and linkage
information175. For some analyses, determining the peptide sequence is as important as
identifying the glycan sequence. With traditional high energy MS/MS like collision
induced dissociation (CID), the glycan structure will fragment primary to the peptide
backbone, thus not providing much peptide information176. Fourier transform ion
cyclotron resonance mass spectrometry (FT-ICR-MS) allows for MS/MS analysis
providing very high mass accuracy and mass resolution and ultimately definite protein
identification177. One soft fragmentation method unique to FT-ICR-MS/MS is electroncapture dissociation (ECD). This method will cleave the peptide backbone without
disrupting the post-translational modifications (PTM), therefore allowing for significant
sequence coverage, including the localization of the PTM, such as N- and O-linked
17S 17R 170

glycosylation

. In addition, this technique is gentle enough to analyze highly

sialylated structures without premature loss of terminal sialic acids180, which allows for
more accurate N-linked oligosaccharide structural identification. Additionally, electron
transfer dissociation (ETD) is a soft fragmentation method similar to ECD, and is
performed in quadrupole ion trap mass spectrometers181. This method also cleaves the
peptide backbone in such a manner to provide sequence and PTM linkage site
information, indicating the utility of this fragmentation platform in glycoproteomic
approaches182. Whether studying intact glycopeptides or cleaved glycans, it is commonly
necessary to desalt the sample and remove organic contaminants prior to mass
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spectrometry analyses, which can be achieved by using column chromatography with
resins such as AG-3, AG-50, CI8, and graphitized carbon '
Finally, when analyzing either glycans or glycopeptides one can either isolate a
single, purified protein as a target, or alternatively, global analysis of glycans from a
given cell type, tissue, or fluid can be performed. Global glycomic analysis can provide
an abundance of information, once its limitations have been addressed. As with
proteomic analyses, the dynamic range of a given biological sample can make mass
spectrometry analyses very difficult. One way to overcome this challenge is to utilize
enrichment techniques such as affinity chromatography, with the most common being
lectin affinity chromatography. Lectins are proteins which specifically bind
monosaccharides, therefore separating out glycoconjugates in a particular sample from
other non-glycosylated molecules. Additionally, if the starting sample material contains
highly abundant proteins that are not of interest (i.e. albumin), then commercially
available kits can be used to remove these contaminating proteins from the given sample,
thus decreasing the dynamic range of the fluid, and increasing the concentration of the
lower abundant targets. Further fractionation of the sample by an online-LC system will
allow for more complete mass spectrometry analysis of global glycosylation patterns of a
particular sample.
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CHAPTER II
DISSERTATION RATIONALE AND SUMMARY OF AIMS

The goal of this research project is to examine the N-glycosylation patterns of
prostate specific antigen (PSA) and prostatic acid phosphatase (PAP) in prostate proximal
fluids, as well as to examine the total glycan profile for prostate proximal fluids with the
intent of discovering carbohydrate-based biomarkers for the detection of early prostate
carcinomas.
Currently, serum PSA is the "gold standard" protein biomarker used in the clinic
for detecting and diagnosing prostate cancer. However, serum PSA levels can be
elevated in non-cancerous conditions as well, such as benign prostatic hyperplasia. This
overlap causes many unnecessary biopsies, radical prostatectomies, and patient anguish.
While other clinical measures are taken into consideration for a more accurate diagnosis,
there is still a great need for better clinical detection methodologies for prostate cancer,
including improved biomarkers. Therefore, the specific hypothesis of this dissertation
is that characterization of the N-linked carbohydrates attached to known prostatederived proteins as well as the N-linked carbohydrates present in prostate-derived
fluids will allow for the discovery of new clinically-relevant biomarkers for the
detection and diagnosis of prostate carcinomas. The specific hypothesis will be tested
by creating disease-defined pools of prostate-derived samples, which will be used in
proteomic and glycomic-based assays utilizing mass spectrometry for the detection of
both glycopeptides and cleaved carbohydrates.
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Initial glycomic and proteomic studies will be completed using seminal plasma
samples, pools of which were created based on their disease status: normal, BPH, or
prostate cancer. These samples will provide ample protein levels of both PSA and PAP
for glycopeptide and glycomic analyses which will add to current knowledge of PSA and
PAP glycosylation. In addition to this sample set, pools of disease-defined expressed
prostatic secretions (EPS) will be generated and subsequently analyzed for detection of
both protein levels and carbohydrate structures of PSA and PAP, as well as examined for
their total glycomic profile. Because EPS fluids are more readily collected in the clinic,
we believe these samples can be used not only for discovery of cancer biomarkers, but
also for their validation and applications in future clinical assays.
The hypothesis of this dissertation was evaluated by addressing the following
specific aims:
Aim I. Develop methodologies for the characterization of N-linked glycans of prostatespecific antigen and prostatic acid phosphatase in seminal fluids. This aim entails:
A. Generating sample sets and fractionation of pools in order to obtain purified
forms of prostate specific antigen and prostatic acid phosphatase. Protein content and
quality will be examined by immunoblotting and MALDI-TOF mass spectrometry.
B. Analysis of PAP glycopeptides by hybrid triple quadrupole/linear ion trap
mass spectrometry in order to better understand which subtypes of carbohydrates are
attached at each N-linked glycosylation site for PAP in seminal plasma samples.
C. Permethylation of cleaved N-linked carbohydrates attached to both PSA and
PAP and analysis of the derivatized structures by MALDI-TOF mass spectrometry.
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Aim II. Establish expressed prostatic secretions as a source of prostate specific antigen
and prostatic acid phosphatase. This aim entails:
A. Collection and preparation of EPS samples for protein-based assays. Both
individual and pooled sample sets will be utilized for the detection of both PSA and PAP.
B. Detection of PSA and PAP in individual samples by LC-ESI mass
spectrometry in order to compare a common urine collection to an EPS urine collection
for the presence of prostate-derived proteins. Additionally, an individual direct EPS
sample will also be analyzed by LC-ESI mass spectrometry for the presence of PSA and
PAP and other prostate-derived proteins.
C. Two-dimensional PAGE analysis and comparison of a urine sample to an EPS
urine sample in order to visualize the different protein patterns between these two types
of fluid collections.
D. Two-dimensional PAGE and immunoblotting analysis of pooled EPS urine
samples for the detection of both PSA and PAP. The ability to visualize the various
isoforms of PSA and PAP in these fluids will allow for further proteomic and glycomic
analyses.
E. Enzyme-linked immunosorbent assay analysis of PSA and PAP concentrations
in individual EPS urine and direct EPS samples. Determining PSA and PAP levels in
these proximal fluids will aid in determining the value of expressed prostatic secretions
as a source of protein-based biomarkers for evaluating prostatic diseases.

Aim III. Application of new methodologies to expressed prostatic secretions for prostate
cancer glycoprotein biomarker discovery. This aim entails:
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A. Generation of EPS urine and direct EPS pools based on disease stratification.
These pools will be concentrated by centrifugal filtration, allowing for enrichment of
targeted glycoproteins. The protein pools will be used for the purification of PSA and
PAP for N-linked glycosylation analysis, as well as for total N-linked glycan analysis by
mass spectrometry.
B. Permethylation of cleaved N-linked carbohydrates attached to both PSA and
PAP and analysis of the resulting derivatized structures by MALDI-TOF mass
spectrometry. Parent masses will be assigned a biologically relevant carbohydrate
structure determined by database searches, and the total structures identified will be
catalogued.
C. Analysis of PAP glycopeptides by hybrid triple quadrupole/linear ion trap
mass spectrometry in order to better understand which subtypes of carbohydrates are
attached at each N-linked glycosylation site for PAP in EPS urine fluids. Both tryptic
and chymotryptic digestions will be utilized in order to obtain more complete coverage of
the N-linked glycopeptides and their corresponding N-glycan structures.
D. Total glycan analysis of permethylated cleaved N-glycans for both EPS urine
and direct EPS fluids by MALDI-TOF/TOF. Disease-defined pools will be compared for
their N-glycan profile, with the intention of determining any differences among disease
states which can be used in future carbohydrate-targeted assays.
E. Computational data analysis of MALDI-TOF spectra using Clinprot software.
Peak intensities of disease-defined pools will be compared to determine if there are any
glycan differences among the sample cohorts.
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In summary, the above Specific Aims will aid in the discovery of carbohydrate
targets for new clinical markers of prostate carcinoma diagnosis and prognosis. Due to
the close link between altered glycosylation and cancer, it is likely that a number of
changes occur to the N-l inked glycans of prostate-derived proteins, all of which should be
detectible with the above glycoproteomic and glycomic platforms. Following discovery
of any N-linked glycosylation alterations present, the target carbohydrates can then be
used in validation assays and subsequently in high-throughput clinical assays. These
tests would utilize the clinically relevant EPS fluids and a multi-well plate platform in
order to allow for rapid results.
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CHAPTER III
AIM I: DEVELOP METHODOLOGIES FOR THE CHARACTERIZATION OF
N-LINKED GLYCANS OF PROSTATE-SPECIFIC ANTIGEN AND PROSTATIC
ACD3 PHOSPHATASE IN SEMINAL FLUIDS

4.1 Introduction
The clinical measurement of the concentration and activities of two prostate
derived glycoproteins, prostate specific antigen (PSA) and prostatic acid phosphatase
(PAP), in serum has been assessed for decades in attempts to detect prostate cancers.
Concentrations of PSA in serum above 10 ng/ml reliably indicate the presence of cancers,
yet PSA testing is limited in its ability to differentiate prostate cancer from benign
prostate hyperplasia (BPH), and specificity of the test diminishes significantly at lower
PSA values below 10 ng/ml37"39. Digital rectal exams (DRE) and determination of serum
prostatic acid phosphatase (PAP) were the principal method for prostate cancer detection
and staging before the advent of PSA testing, and they too have many limitations185'186.
Serum PAP levels can still be used as an indicator of metastatic disease and possibly
recurrence prediction48'49, but it has proven to have low specificities and sensitivities as a
detection biomarker as compared to PSA33. While X-ray crystal structures have been
reported for both human PSA and PAP124'187, there was little resolution of the glycan
constituents of these proteins. Because of the known associations of changes in
glycosylation associated with cancer progression83"86, characterization of the glycan
constituents of PSA and PAP derived from clinical samples representing healthy and

Reproduced with permission from Journal ofProteome Research 8 (2): 620-623, 2009.
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different prostatic disease states could identify knew biomarker candidates for prostate
cancer detection.
PSA contains 8% carbohydrate by mass119, and has one glycosylation site at
asparagine (Asn)-45120. Previous studies on PSA glycosylation have compared seminal
plasma from healthy donors to prostate tumor metastatic cell line LNCaP115"117. PSA
purified from the seminal fluid of healthy subjects have been characterized as having
sialylated complex biantennary glycans, frequent core fucose modifications, high
mannose glycans, and some terminal N-acetylgalactosamines117'121. PSA glycans isolated
from LNCaP cell lines have also been characterized as having some triantennary
structures116, as well as decreased sialic acid content and the presence of increased fucose
and GalNAc content115. A recent comparison of the sialic acid content of free PSA and
proPSA isolated from serum, seminal plasma and tissues from non-cancer control
subjects and prostate cancer subjects was reported

. Essentially no differences in

sialylation content for the different forms of PSA were detected for any condition or
sample122. A separate study of serum PSA derived glycans compared structural
differences between free and complexed PSA123. Both forms of PSA were found to have
mostly sialylated and fucosylated biantennary structures, while a few multiantennary
complex structures were also identified

. These previous studies did not evaluate the

specific structural configurations for each oligosaccharide isolated, and very few numbers
of clinical samples were used. PAP has three glycosylation sites at Asn-62, Asn-188, and
Asn-301124,125, making it a more difficult target for site specific structural
characterization, yet one that may be a suitable complement to PSA. An X-ray crystal
structure of PAP from normal seminal plasma had reported that Asn-301 had glycan
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modifications consisting of primarily high mannose oligosaccharides, while glycans at
Asn-188 were less resolved, but consistent with complex structures containing sialic acid
and fucose124. In relation to prostate cancer, a previous serial lectin analysis of PAP
isolated from tissue in BPH and cancer subjects reported a decrease in high-mannose and
hybrid glycans with core fucoses in cancer relative to BPH, and an increase of nonfucosylated hybrids in PCa as compared to BPH125.
The objective of our study described herein was to obtain purified forms of both
PSA and PAP from a clinical cohort of seminal plasma from healthy, BPH and prostate
cancer subjects for further glycan structural analyses. We hypothesized that
characterization of these PSA and PAP glycoforms across specified clinical sample sets
would identify a subset of glycan constituents as biomarker candidates for the detection
of prostate cancers. Following a purification step using thiophilic chromatography, the
released glycans from PSA and PAP were characterized using HPLC separation of
aminobenozate derivatives, permethylation and MALDI-TOF/TOF profiling, and
glycopeptide analysis on a hybrid triple quadrupole/linear ion trap mass spectrometer.
The cumulative structures obtained for both PSA and PAP are reported and potential
disease specific classes of glycoforms are identified. Specific assignments of glycan
structural subtypes have also been determined for each of the three glycosylation sites on
PAP. The glycan structures reported for PAP represent the first description of its glycan
constituents using mass spectrometry based methods.
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4.2 Experimental
Seminal plasma samples
Seminal fluid was obtained from men seen at the EVMS Department of
Urology/Divine Tidewater Urology clinic for prostate cancer screening from 1989-2003.
A semen collection kit was provided for each donor. Following semen collection, an
instant freeze pack was applied to each tube for storage, and brought with the donor to
the urology clinic. Following transport to the Virginia Prostate Center biorepository at
EVMS, each sample was thawed, centrifuged to remove sperm, and stored in 0.5 ml
aliquots. Initially, Normal (n=65), BPH (n=59), and PCa (n=92) pools (8-10 mis
total/pool) were compiled from samples previously aliquoted for expression profiling
studies (0.05 to 0.2 ml per sample), and matched for age. Each aliquot went through less
than 2 freeze/thaw cycles, and average serum PSA values were 10.4 ng/ml (range 0.01 225.8 ) for PCa, 3.6 ng/ml (range 0.15 - 13.9) for BPH, and 1.5 ng/ml (range 0.3 - 4.8) for
normal. The pooled samples were then subjected to a low-speed spin (4°C, 12k RPM, 20
minutes) to remove any cellular contaminants, followed by ultracentrifugation (4°C, 37K
RPM, 1 hour) to pellet out the prostasomes (membrane-bound storage vesicles secreted
by prostate epithelial cells188). The supernatant was collected and 400ul aliquots were
stored at -80° C. A more defined subset of seminal plasma pools were created for each
clinical group, with each cohort having defined serum PSA values in the 2-7 ng/ml range.
Nine samples, 500ul per sample, were used to make each seminal plasma pool, and the
samples used were collected between 1997 and 2003. The mean serum PSA values were
3.58 ng/ml for normal, 2.64 ng/ml for BPH, and 5.83 ng/ml for prostate cancer. BPH
cases were defined as being biopsy negative, and the cancer samples were predominantly
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Gleason grade 6 (3+3). These pools were processed as previously mentioned. The final
supernatant of approximately 4.5 ml was aliquoted and stored at -80°C until needed.
Protein concentrations were determined for all seminal plasma pools.

Thiophilic adsorption chromatography (TAC)
PSA and PAP were purified from seminal plasma pools using thiophilic
adsorption chromatography (TAC) following the methods outlined by Kawiniski et al.189.
Thiophilic adsorption chromatography uses a resin that consists of sulfone and thioether
groups bound to agarose beads, which in turn binds proteins primarily via tryptophan and
phenylalanine residues189"191. Briefly, seminal plasma pools were applied to Fractogel®
EMD TA "T-gel" (Merck KGaG, Darmstadt, Germany) columns (2 cm x 0.5 cm)
equilibrated in 1M sodium sulfate, and eluted in decreasing salt fractions. Protein content
of each pool was normalized to 3.0 mg, with the samples in a final volume of 1ml in
25mM HEPES/1M sodium sulfate. Next, the sample was applied to the column,
followed by 2ml of column buffer, and allowed to flow through by gravity; this three
milliliter fraction collected is named "unbound". The column was washed with 8 bed
volumes of column buffer. Batch elution with decreasing sodium sulfate molarities
(0.8M, 0.6M, 0.4M, 0.2M, and 0.0M) was performed using a low-pressure peristaltic
pump. For each concentration, approximately 3ml fractions were collected, aliquoted, and
stored at -80°C. The presence of PSA and PAP were confirmed by Western blot, and
MALDI peptide massfingerprintingof the corresponding excised gel bands was done to
assess relative purity. MASCOT scores of greater than 100 and sequence coverage of
greater than 45% were routinely observed for both PAP and PSA bands.
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Normal Phase HPLC
Rapid glycan sequencing of both PSA and PAP was performed by using
previously optimized procedures192. Briefly, PSA and PAP gel slices were digested with
PNGase F, then the released free glycans were labeled with 2-aminobenzamide (2-AB)
for subsequent normal phase HPLC analysis193. A subset of samples were treated with
Arthrobacter ureafaciens sialidase as previously described by Guile et al.194. The
resulting peaks, separated by time of appearance, correspond to specific glycan structures
on the basis of glucose unit values (data not shown)194. All HPLC analyses were
performed using a Waters Alliance HPLC System and quantified using the Millennium
Chromatography Manager (Waters Corporation, Milford, MA).

N-glycan permethylation
TAC-purified PSA and PAP gel bands derived from seminal plasma pools were
permethylated195 following trypsin digestion. Gel bands were first reduced and alkylated,
and then dried in vacuo prior to proteolytic digestion. Trypsin digestions were performed
at 37°C for 18 hours, followed by peptide extraction with 50% acetonitrile/0.1% TFA and
dried in vacuo. Next, trypsin was denatured by heating the sample at 100°C for 5
minutes, and 1500 units of PNGase F (New England Biolabs, Ipswich, MA) was added to
the peptide mixture and incubated at 37°C for 18 hours. The final digested product was
purified using Resprep™ CI8 cartridges (Restek Corporation, Bellefonte, PA). The Nglycan fraction was collected in 5% acetic acid, and subsequently dried under reduced
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pressure. Dried N-glycans were permethylated following the protocol described by
Ciucanu and Kerek195. The permethylated N-glycans were purified using CI8 columns,
eluted in 85% acetonitrile, and then dried under a nitrogen stream.

MALDI-TOF/TOF
The dried permethylated N-glycans were reconstituted in 20 microliters of 100%
methanol. Sample was mixed 1:1 with 2,5-Dihydroxybenzoic acid (DHB) matrix
(20mg/ml in 50% methanol) and spotted on a polished steel MALDI-TOF target plate
and allowed to crystallize at room temperature in the dark. Each sample was analyzed in
positive ion mode using an UltraFlex III MALDI-TOF/TOF instrument (Bruker
Daltonics, Germany). FlexControl and FlexAnalysis software (Bruker Daltonics,
Germany) were used for spectra processing. Additionally, the glycan database offered by
the Consortium for Functional Glycomics (http://www.functionalglycomics.org) was
used to search permethylated glycan masses correlating to peaks of interest in MALDITOF spectra. Glycan "cartoons" representing mass peaks were built using GlycanBuilder
ver 1.2 build 3353196.

Hybrid triple quadrupole/linear ion trap mass spectrometry
A hybrid triple quadrupole/linear ion trap mass spectrometer 4000 (QTRAP®
LC/MS/MS system, Applied Biosystems, Foster City, CA) coupled to a Tempo NanoLC
system (Eksigent Technologies, Dublin, CA) was used to determine the structures of the
glycans attached to each of the three PAP linkage sites: Asn-62, Asn-188, and Asn-301.
The methods described by Sandra et al.197 were used with minor modifications to
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optimize for our samples and instrumentation. Briefly, TAC-purified PAP gel slices
derived from seminal plasma were reduced, alkylated, and digested with a saturated
solution (in 50mM ammonium bicarbonate) of either 750 ng of trypsin or 950 ng of
chymotrypsin. After an overnight digestion, the resultant peptides were extracted from
the gel slice using 50% acetonitrile/0.1% TFA in water and dried in vacuo. The digested
product was reconstituted in 20 microliters of Buffer A (5% acetonitrile/0.1% formic
acid/0.005% heptafluorobutyric acid in water) and 8 microliters was injected into the
nanoLC system for fractionation and analysis. Both the linear ion trap and the triple
quadrupole capabilities of the QTRAP were utilized in these analyses. Glycopeptides
were identified in the digestion mixtures by monitoring for unique marker oxonium ions
such as m/z 163 (Hex*), 204 (HexNAc+), 292/274/256 (NeuAc+1), and 366
(HexHexNAc+) that originate from fragmented glycopeptides197'198. In this approach the
peptides are scanned in quadrupole 1 (Ql) to determine their masses and retention times.
The peptides are then transmitted to quadrupole 2 (Q2) which acts as a collision cell
where fragmentation occurs. Quadrupole 3 (Q3) is set to transmit only the mass of the
diagnostic oxonium ions. Upon their detection, an enhanced product ion scan (EPI) of
the precursor ion is triggered where fragmentation occurs in Q2, the fragmented ions are
captured in the ion trap and then scanned out generating an MS/MS spectrum containing
the ions from the both the peptide and the linked carbohydrate structures.

4.3 Results
Purification of PSA and PAP from seminal plasma pools
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A large repository of seminal plasma fluids collected over the last 18 years were
used to create pooled sample cohorts representative of normal control, benign prostatic
hyperplasia (BPH) and prostate cancer conditions. A thiophilic adsorption
chromatography (TAC) approach adapted from Kawiniski et al.189 was used to purify
PSA and PAP from the prostasome depleted, pooled seminal plasma fluids. Following
sequential batch elution, the resulting protein fractions were separated by SDS-PAGE, as
shown in Figure 5. Under the conditions used, PAP did not bind to the TAC resin, and
PSA eluted in both the 0.6M and 0.4M sodium sulfate fractions. Both PSA and PAP were
readily detected by Coomassie staining, and their identities were confirmed in their
respective fractions by western blotting and peptide mass fingerprinting. For both PSA
and PAP isolated from gel slices, MASCOT scores of over 100 and sequence coverage of
at least 45% were obtained. Lastly, there was no indication of other protein sequences
present with significant scores.

Rapid glycan sequencing analysis of PAP and PSA glycans
The TAC fractions containing PSA and PAP were used for preparative SDS-PAGE
separations, stained with Coomassie blue, and gel slices corresponding to PSA or PAP
excised. Each gel band was digested with trypsin, followed by PNGaseF digestion and 2aminobenzamide derivatization of the released glycans as previously described193.
Glycans from PSA and PAP for each of the three clinical groups were then separated by
normal phase HPLC and their elution positions used to define structural classes194. The
elution profile of PAP derived 2AB modified glycans from each pool is shown in Figure
6. It is clear that there are major differences in glycosylation patterns detected for PAP,

M

1

2

3

4

5
4

PAP

6

*

PSA

Figure 5. Seminal plasma fractionation by thiophilic adsorption chromatography.
Seminal plasma protein fractions purified by thiophilic adsorption chromatography
(TAC) were separated on a 12% Bis-Tris NuPAGE SDS-gel (Invitrogen) and stained
with Coomassie blue. Unbound proteins are shown in Lane 1, with protein from the 0.8M
NaS04 elution in Lane 2, 0.6M (Lane 3), 0.4M (Lane 4), 0.2M (Lane 5) and 0 M/25mM
HEPES (Lane 6). This gel shows the proteins from normal seminal plasma, and is
representative of the purifications of the benign and cancer samples. PAP and PSA
identities were confirmed in the above fractions by staining, western blots and MALDITOF analysis.
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Figure 6. Normal phase HPLC separation of 2-AB derivatized N-linked glycans
from PAP. The relative levels of N-linked glycans from PAP isolated from normal
control, benign (BPH) and prostate cancer (PCa) conditions separated by normal phase
HPLC. Structural designation are as follows: A1G1, hybrid glycan with a single galactose
residue on the 1,6 arm; FcA2, core fucosylated (1,6) agalactosylated biantennary glycan;
Man6, High mannose glycan with 6 mannose residues, A2G2, biantennary N-glycan;
Man7, High mannose glycan with 7 mannose residues; A3G3, triantennary N-linked
glycan; FcA3G3, core fucosylated (1,6) triantennary N-linked glycan; A4G3,
tetraantennary N-linked glycan with 3 galactose residues; A4G4, tetraantennary N-linked
glycan; FcA4G4, core fucosylated (1,6) tetraantennary N-linked glycan. B indicates
bisecting GlcNAc residues.
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particularly in the comparison of healthy and benign relative to the cancer samples.
Because of the known instabilities of terminal sialic acid residues during processing and
HPLC analysis26, digestion with Arthrobacter ureafaciens sialidase was also done prior
to normal phase HPLC separation to compare the non-sialylated structures. As
summarized in Figure 7, there were still significant decreases in the fucosylated bi- and
tetraantennary classes, FcA2G2 and FcA4G4, in the cancer samples. Either with or
without sialidase treatment, there was also an apparent decrease in high mannose (Man6)
structures in the cancer samples, and dramatic increases in cancer for truncated A1G1
structures. A similar analysis for 2-AB labeled PSA glycans was done, as summarized in
Figure 8 (no sialidase) and Figure 9 (with sialidase). Cumulatively, the types of glycan
structures detected in these HPLC separations are consistent with previously reported
structures for PSA115"117. There were no dramatic differences in expression of sub-types
across the three clinical conditions, with the exception of the A2G2 structures in BPH in
the non-sialidase treated preparation. Because this difference was not detected in the
sialidase treated samples, this could reflect differential stabilities or sample processing
differences. This will need to be further investigated in follow up studies.
The seminal plasma pools used for these initial analyses represent a broad range
of clinical samples reflecting the disease severity spectrum of prostate cancers and benign
conditions collected from 1990 to 2003, a time frame that spans the pre-PSA testing era
to current clinical practice. Using the PSA levels for each individual in the pool of these
samples, a refined pooled subset of 9 samples per condition was generated based on dates
of collection after 1997 and serum PSA levels between 2-7 ng/ml. This PSA range better
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Figure 7. Normal phase HPLC separation of 2-AB derivatized N-linked glycans
from PAP treated with sialidase. N-linked glycans from PAP isolated from normal
control, benign (BPH), and prostate cancer (PCa) were treated with sialidase prior to
normal phase HPLC separation. Shown are the relative intensities of each indicated
structure per condition, normal (Gray bars); BPH (Black bars); PCa (White bars).
Structural abbreviations are described in the legend for Figure 6.
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PSA Glycans (no sialidase)

Figure 8. Normal phase HPLC separation of 2-AB derivatized N-linked glycans
from PSA. N-linked glycans from PSA isolated from normal control, benign (BPH) and
prostate cancer (PCa) were separated by normal phase HPLC. Shown are the relative
intensities of each indicated structure per condition, normal (Gray bars); BPH (Black
bars); PCa (White bars). Structural abbreviations are described in the legend for Figure 6.
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Figure 9. Normal phase HPLC separation of 2-AB derivatized N-linked glycans
from PSA treated with sialidase.
N-linked glycans from PSA isolated from normal control, benign (BPH), and prostate
cancer (PCa) were treated with sialidase prior to normal phase HPLC separation. Shown
are the relative intensities of each indicated structure per condition, normal (Gray bars);
BPH (Black bars); PCa (White bars). Structural abbreviations are described in the legend
for Figure 6.
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reflects the majority of benign and prostate cancer subjects detected in the PSA
screening/testing era, and hence results from these samples should be more reflective of
current urological practice. The same sample preparation and TAC purification was done
for each new pool. PAP and PSA eluted in their respective fractions as described in
Figure 5 (Figure 10). As shown in Figure 11 for PAP, similar results to the larger pool
data were obtained. There continued to be a larger proportion of fragmented glycans
(A1G1, FcA2, A2G1, FcA2) in the prostate cancer samples relative to the healthy and
BPH cohorts. PSA and PAP purified from this new cohort was used for all subsequent
analyses.

MALDI-TOF analysis of permethylated PSA and PAP glycans
In order to further define the structural repertoire of PSA and PAP glycans,
permethylation195 of the PNGase F released glycans was done for each clinical cohort,
followed by MALDI-TOF/TOF analysis. Because of the broad diversity of the indicated
structural classes from the HPLC analyses, the goal was not to identify disease specific
changes, but to better define all of the possible glycan structures detected on seminal
plasma PSA and PAP. Permethylation of glycans aids in the stability of the terminal
sialylated residues for detection by MALDI-TOF/TOF, and simplifies the spectra to
primarily Na+ adducts, allowing for less complex annotation of mass peaks. From the
permethylation experiments, we were able to detect multiple glycoforms for both PAP
and PSA (Table 2 and Table 3). A representative MALDI-TOF spectra of PAP derived
permethylated glycans from prostate cancer samples are shown in Figure 12.
Cumulatively, 21 structural classes of PAP glycans were detected representing primarily
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Figure 10. Thiophilic adsorption chromatography of redefined seminal plasma
pools. Seminal plasma protein fractions from normal, BPH, and PCa defined pools
purified by thiophilic adsorption chromatography (TAC) were separated on a 12% BisTris NuPAGE SDS-gel (Invitrogen) and silver stained. Proteins that did not bind the
TAC resin are shown in the lane marked Unbound, with protein from the 0.8M NaS04
elution in Lane 1, 0.6M (Lane 2), 0.4M (Lane 3), 0.2M (Lane 4) and 0 M/25mM HEPES
(Lane 5). PAP and PSA identities were confirmed in the above fractions by staining,
western blots and MALDI-TOF analysis.
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following normal phase HPLC separation: normal (Gray bars); BPH (Black bars); PCa
(White bars). Structural abbreviations are described in the legend for Figure 6.
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Table 2. Permethylated MALDI-TOF m/z and corresponding N-glycan structures
for PAP
Number

m/z

Proposed Gtycan Structure

1

1784.016

M6N2

2

1987.958

M7N2

3

2070.189

GaGN2M3N2

4

2244.268

GaCN2M3tJ2F

Sub-Type

High Mannose

*'"

.

:

:

High Mannose

•

•

•

•

Complex

Complex
*

• • • •

5

2314.091

Hex5HexNAc5

Complex

6

2432.339

NeuAc1Gal2N2M3N2

Complex

7

2806.425

NeuAc1Gal2N2M3N2F

6

2793.503

NeuAc2GaCN2M3N2

•

: : • • •
Complex

:

: : • • •

•

• "> • •

Complex

9

2881.559

NeuAc1GaON3M3N2

Complex

10

2967.587

NeuAc2GaGN2M3H2F

Complex

11

3055.647

NeuAc1GaBN3Prf3N2F

12

3242.719

NeuAc2GaQN3M3N2

Complex

13

3416.793

NeuAe2GaQN3M3N2t-

Complex

14

3504 838 NeuAc1GaWN4M3N2F

15

3603.894

NeuAc3GaBN3M3N2

Complex

16

3777.971

NeuAc3GaQN3f.!3N2F

Complex

17

3867.027

NeuAc2Gal4N4M3N2f

18

3963 779 Hex6HexNAc5NeuAtf •

19

4053.873

20

21

*

" • ' * • • •
Camp test

x2 I !'" * *

"

•

Complex

• *;. • •

x2

" ,
*

Complex

• •"

Complex

NeuAc3GaWN4M3N2

• ,
"

Complex

4227.294

NeuAc3Gal4N4M3N2f

"

Complex

4588.57

NeuAc4GaBN4M3N2F

• *

Complex

x3

•

Permethylated PAP glycans from normal, BPH, and PCa seminal plasma pools were
analyzed by MALDI-TOF. Identified m/z values were used for database searches, and
corresponding masses that could be assigned to a biologically relevant N-glycan structure
are listed. An asterisk denotes structures that are one representation of multiple possible
glycoforms for a given mass. The shown structure in these cases was chosen based on its
apparent prevalence in mammalian species. Cartoon representations are as follows: •
=GlcNAc, • =Mannose, O =Galactose, A=Fucose, ^=NeuAc, D=GalNAc
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Table 3. Permethylated MALDI-TOF m/z and corresponding N-glycan structures
for PSA
Number

m/z

1

1344.917

Proposed Glvcan Structure

Sub-Type

Number

Complex

21

m/z

Proposed Glycan Structure

:••• • •
M3N2F

*

1580069

M5N2

3

1590.051

NM3N2F

» »

> • •

*

* • •

2767.61 Hex5dHex4HexNAc4

*
2

Sub-Type

Complex
* •

•

>

• •

Hiqh Mannose

22

2779.64 NeuAc1Gal2N2M3N2F2

Complex

23

2793.652 NeuAc2Gal2N2M3N2

Complex
:

: > • •

Complex

•-•-,

•
•

4

1784.208

High Mannose

1907.156

24

2880.654 NeuAc1Gal3N3M3N2

m •
• • • •

*
5

N3M3N2

Complex
* • •'

Complex

25

2893.731 Hex4dHex1HexNAc6NeuAc1

2111.231

Hax4HexNAc5

Complex

26

2967.686 NeuAc2Gal2N2M3N2F

7

2244.425

Gal2N2M3N2F

Complex

27

3024.789 NeuAc1Gal2N3M3N2F2

8

2315.331

Hex5HexNAc5

Complex

28

3132.772 Gal6N3M3N2

• •

v

•_•/* "

*

''

*
6

• % » •

*

M6N2

'.

Complex

! > • •

Complex

• *>. •
m

*

N/A

••-•'
" >
-.--,:• m • '

•

•

Complex

I- •_

9

2356.626

• > • .
• *

Hex4HexNAc6

Complex

29

3142.734 Gal4N4M3N2F

Complex
• •

10

2377.634

Hybnd

Hex6dHex2HexNAc3

30

3211.806 NeuAc2Gal2N3M3N2F

• •
X2

• „ • • •
. •

•
11

2419.445

Hex5dHex2HexNAc4

Complex

31

3242.891 NeuAc2Gal3N3M3N2

x2

*
Complex

•'...
.->..'
•

Complex

a.

> • •••

12

2432.413

•

• '

Complex

NeuAc1Gal2N2M3N2

32

3345.936 Hex8dHex1HexNAc5

•'* > • •
13

2472.384

NeuAc1GalN3M3N2

14

2518.443

Gal3N3M3N2

15

2549.473

Hex6dHex3HexNAc3

16

2561.577

Hex5HexNAc6

• •""> • •
- • •

» T

**

2593.532

• •
V
*

Complex

33

3416.859 NeuAc2Gal3N3M3N2F

Complex

34

3593.05 Hex8dHex1HexNAc7

Hybrid

35

3605.045 NeuAc3Gal3N3M3N2

Complex

Complex

36

3777.062 NeuAc3Gal3N3M3N2F

Complex

Complex

37

3866.523 NeuAc2Gal4N4M3N2F

•

T
• •

Hex5dHex3HexNAc4

x2

• . . » •

;;:.
Complex

'
18

2606.502

NeuAc1Gal2N2M3N2F

Complex

38

2677.545

NeuAc1Gal2N3M3N2

20

2694.766

Gal3N3M3N2F

- •

• * . . .

3912.098 Hex9dHex1HexNAc6NeuAc

Complex
m

•.
• * • - •
19

Complex

Complex

•

• •

1

17

• •

Complex
- •v
* ' •'*"•• • •
x2 •> m •'

Complex

39

3966.198 Hex6HexNAc5NeuAc4

Complex

40

4416.599 NeuAc4Gal4N4M3N2

*- • > • •
* •-• • m

Complex

: : ' ; - • •
Complex

Permethylated PSA glycans from normal, BPH, and PCa seminal plasma pools were
analyzed by MALDI-TOF. Identified m/z values were used for database searches, and
corresponding masses that could be assigned to a biologically relevant N-glycan structure
are listed. An asterisk denotes structures that are one representation of multiple possible
glycoforms for a given mass. The shown structure in these cases was chosen based on its
apparent prevalence in mammalian species. Cartoon representations are as follows: •
=GlcNAc, • =Mannose, O =Galactose, A=Fucose, ^=NeuAc, D=GalNAc
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Figure 12. MALDI-TOF analysis of permethylated PAP glycans from prostate
cancer seminal plasma. A representative MALDI spectrum for permethylated PAP is
shown. Combined with the structures determined in the control and BPH permethylated
PAP samples, glycan structures corresponding to detected m/z peaks are listed in Table 2.
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high-mannose and complex sub-types, with a few potential hybrid sub-types represented
as well (Table 2). Permethylated glycans cleaved from PSA seemed to be mostly bi- and
tri-antennary structures of the complex sub-type, but represented 40 potential classes,
including high mannose and hybrid sub-types detected as well (Table 3). These results
are consistent with structures previously reported for PSA glycans from serum and
seminal fluids115"117122.

Triple-quadrupole mass spectrometry analysis of PAP glycopeptides
Because PAP has three distinct glycan sites, and the previously reported crystal
structure was only able to definitively assign one high-mannose containing site,
individual glycopeptide analysis of the three sites was initiated. SDS-PAGE separated
PAP was proteolytically digested with trypsin or chymotrypsin, and peptides fractionated
by nanoLC system in-line with triple quadrupole mass spectrometer. The instrument was
operated in the precursor ion (PI) scan mode for individual sugar molecules at specific
m/z values of either 163 for Hexose+1(Hex), 204 for N-acetylhexoseamine+1 (HexNAc),
292/274/256 for N-acetylneuraminic acid+1 (NeuAc), or 366 for Hex-HexNAc+1. An
enhanced product ion scan is triggered upon detection of the specified diagnostic ion,
generating information on the sugar composition and the amino acid sequence of the
glycopeptides in a single assay. An example is shown in Figure 13 for the tryptic peptide
with one missed cleavage encompassing the high mannose site at Asn 301
(GEYFVEMYYRNETQHEPYPLMLPGCSPSCPLER), as determined by the precursor
ion scan for oxonium ion 163. Knowing the parent mass allows for annotation of the
remaining triply charged ion peaks in the third quadrupole (Q3) for identification of sugar
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Figure 13. Precursor ion scan for 163 m/z hexose of tryptic PAP peptides.
A) Enhanced Product Ion (EPI) scan of a quadrupole-charged PAP glycopeptide with
parent mass of 5449.0.
B) Expanded window of above EPI scan showing fragmentation of the parent ion that
corresponds to the tryptic peptide GEYFVEMYYRNETQHEPYPLMLPGCSPSCPLER
containing the glycosylation site Asn-301 and a Man6 N-glycan.
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constituents and fragments. The annotation of these glycans was greatly simplified as this
site contains only high mannose structures, with Man6 being the major constituent, and
Man7 a minor one, which is consistent with the PAP crystal structure124. Additionally,
Figure 14 illustrates an example of the tryptic peptide with one missed cleavage
encompassing the high mannose site at Asn 62 (FLNESYKHEQVYIR), as determined by
the precursor ion scan for oxonium ion 292. As listed in Table 4, this approach has been
useful for identifying complex biantennary and triantennary glycans at Asn 62. This site
had previously been poorly resolved in the PAP crystal structure, such that complex
glycan structures were proposed to be unlikely constituents9. Like in the crystal
structure, the site at Asn 188 has proven elusive to glycan analysis, particularly when
trypsin was used for digestion, which we believe was due to a combination of mixed
tryptic cleavages combined with large tetra-antennary glycans. However, use of
chymotrypsin allowed detection of an Asn 188 containing glycopeptides, consistent with
attached tetraantennary glycan structures (Table 4).

4.4 Discussion
The need for improved prostate cancer biomarkers beyond the serum PSA test is
increasingly evident. Because this test is applied to population screening, there is a
wealth of data that indicates its strength in increasing detection of prostate cancers, but its
use has also led to increased over-treatment and unnecessary surgeries for indolent
disease. Despite its widespread use, there is still much characterization of PSA to be
done, particularly in regards to its structural glycosylation properties and physiological
function. Proximal fluids of the prostate like seminal fluid that are enriched for prostate
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Figure 14. Precursor ion scan for 292 m/z hexose of tryptic PAP peptides.
A) Enhanced Product Ion (EPI) scan of a quadrupole-charged PAP glycopeptide with
parent mass of 3744.0.
B) Expanded window of above EPI scan showing fragmentation of the parent ion that
corresponds to the tryptic peptide FLNESYKHEQVYIR containing the glycosylation site
Asn-62 and a complex biantennary, singly sialylated N-glycan.
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Table 4. PAP glycopeptides with corresponding N-glycan structures identified by
QTRAP
N-linked Glycosylation site

Peptides generated by enzymatic digestion

Structures Identified

Trypsin Digestion
FLNESYKHEQVYIR 1825.9
KFLNESYKHEQVYIR 1954.0

Asn-62
Cymotrypsin Digestion
RKFLNESYKHEQVY 1840.9

Trypsin Digestion
N/A

:

:> •-

• •-•

"> • •

•-o-»-«'

• -.~ • •. . . • • •

Asn-188
Chymotrypsin Digestion
CESVHNFTLPSW 1476.7
DPLYCESVHNFTLPSW 1964.9
YCESVHNFTLPSWATEDTM 2304.0

X3 i--"-»•'
•o-r

Trypsin Digestion
NETQHEPYPLMLPGCSPSCPLER 2712.2
GEYFVEMYYRNETQHEPYPLMLPGCSPSCPLER 4049.9

«... > - • - •

Asn-301
Chymotrypsin Digestion
RNETQHEPYPLM 1530.7
RNETQHEPYPLMLPGCSPSCPLERF 2974.3

':">••

Both tryptic and chymotryptic PAP digests were analyzed by the QTRAP as described in
the experimental section. PI scans for oxonium ions 163, 366, and 292 are represented in
the above table. Certain EPI scans revealed glycopeptide information that allowed for the
assignment of both peptide and glycan.
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derived secreted glycoproteins like PSA have long been a source of this enzyme,
particularly as it is generally present at concentrations that range from 100-400 ug/ml in
this fluid. Using a large cohort of archived seminal plasma samples reflective of healthy,
benign and prostate cancer conditions allowed systematic characterization of PSA for
similarities and differences in its disease specific glycosylation patterns. While PSA
glycosylation has been previously studied by many other groups

'

, to our

knowledge we are the first to examine PSA glycoforms across matched, disease-defined
sample sets reflective of multiple samples. For a glycoprotein with one site of Nglycosylation, the number of different glycan structures identified across the conditions
analyzed is highly variable, ranging from predominant complex bi- or tetraantennary
structures, to hybrid and high mannose glycoforms. In this regards, use of pooled
samples to identify disease specific variants of PSA will be highly limiting. While it is
appropriate to define the repertoire of potential structures, there were no conclusions that
could be reached regarding specific disease glycoform variants of PSA. Methods that
facilitate characterization of individual samples like targeted lectin-ELISA assays199 or
specific selective reaction monitoring (SRM) approaches using instrumental
configurations like the hybrid triple quadrupole MS assay for PAP will be necessary to
better define disease specific glycoform changes for PSA. The diversity of glycan
structures detected for PSA, and the well established role of PSA in clinical medicine and
prostate disease, certainly warrant these types of approaches on larger sample cohorts.
The cumulative glycan results for PAP represent the first characterization of PAP
structures using mass spectrometry approaches. Previous reports indicated that PAP
glycosylation at Asn-301 was of the high-mannose type, while it was hypothesized that
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the Asn-188 site contained complex-type glycans and the Asn-62 site contained noncomplex structures124. Our results confirm that high-mannose glycoforms are present at
the Asn-301 site, with the presence of Man6 and Man7 glycans observed for this site.
Based on the data summarized in Table 4, we have found that sialylated complex-type
glycans occupy the site at Asn-62, with bi- and tri-antennary structures present. The
glycans attached to Asn-188 are less defined, but the preliminary results indicate a larger
glycan constituent, most likely the tetra-antennary complex sialylated and fucosylated
structures observed in the characterization studies (Table 3). Clearly, application of
alternative proteases besides trypsin could better clarify the glycopeptide constituents of
the Asn-188 site. Emerging improvements in computer programs like SimGlycan
(Applied Biosystems/PremierBiosoft) that allow annotation of large complex glycan
constituents will also facilitate this characterization. Conversely, the HPLC and MALDITOF profiling indicated the presence of truncated glycan species predominantly in the
prostate cancer samples. Their further characterization at the structural level, as well as
their site of attachment, could lead to specific PAP glycan biomarker assays.
Additionally, the described purification and analysis approaches for both PAP and PSA
glycans are compatible with emerging quantitative isotope labeling strategies200. Missing
for both PAP and PSA are any determinations of the anomeric linkages for the different
glycan species, as linkage differences and positions of the sialic acid residues in
particular could dictate biological and clinical differences. The permethylation strategies
already utilized are equally valid for providing PSA and PAP glycans for more detailed
MS/MS" structural characterization approaches201'202, and these are currently ongoing in
our laboratories.
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The cumulative glycan structural information from PSA and PAP is being used in
a prostate cancer biomarker "pipeline" to develop specific lectin-ELISA assays199
targeting fucosylation and sialylation differences, as well as targeted SRM and/or
multiple reaction monitoring (MRM) assays in proximal prostatic fluids. These
approaches are particularly advantageous for the analysis of many individual seminal
plasma samples, as well as other proximal prostatic fluids termed expressed prostatic
secretions (EPS) being collected for molecular genetic biomarker assays74' m . Expressed
prostatic secretions are collected in voided urine following a standard urological digital
rectal exam combined with prostate massage, and analysis of their glycoprotein
constituents could complement and extend results reported in seminal plasma. In
conclusion, there are multiple glycan targets of potential clinical relevance that warrant
continued structural analysis of PAP and PSA glycopeptide species. The use of seminal
plasma derived proteins will continue to facilitate this characterization, and can also be
readily adapted to other clinical relevant proximal fluids of the prostate.
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CHAPTER IV
AIM II: ESTABLISH EXPRESSED PROSTATIC SECRETIONS AS A SOURCE
OF PROSTATE-SPECIFIC ANTIGEN AND PROSTATIC ACID PHOSPHATASE

5.1 Introduction
Expressed prostatic secretions (EPS) are fluids derived directly from the prostate,
which can be collected in different manners. EPS fluids have been routinely collected in
the clinic since the late 1960's for the purpose of the diagnosis of chronic prostatitis and
inflammatory chronic pelvic pain syndrome131203'204. Historically for the analysis of
prostatitis, the prostate is forcefully massaged and the small amount of prostatic fluid is
collected from the penis204, however this procedure can cause considerable pain for the
patient. A second method involves squeezing the prostate ex vivo following a
prostatectomy and collecting the fluid that drips from the gland205. A third method can
be performed by the urological surgeon prior to surgery whereby the prostate is
vigorously massaged while the patient is under anesthesia and prostatic fluid is pushed
through the urethra and collected from the penis. It is this third method that is used to
collect the direct EPS samples analyzed in this dissertation. A fourth method, and easiest
to obtain clinically, is the collection of EPS in voided urine following a routine digital
rectal exam (DRE) in the clinic. In this case, the prostate is gently massaged on both
sides during the DRE exam, and is comparably less painful for the patient relative to the
other collection methods. These fluids not only contain secreted proteins from within the
prostatic infrastructure, but they also contain epithelial cells that are shed during the
massaging process. EPS fluids are considered proximal fluids of the prostate and
Figures 17 and 18 are adapted from Drake, RR et al., J of Proteomics. 2009 Aug 20;72(6):907-917.
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therefore have potential as a rich source of biomarkers for prostatic diseases, especially
cancer. In recent years, EPS fluids have been used for the development of genetic-based
assays for prostate cancer detection have gained increased popularity74' 132-134>206-210 A
subset of these assays focus on the cellular sediment obtained from EPS fluids for the use
in prostate cell-associated PCA3 mRNA testing (APTIMA PCA3, Gen-Probe Inc, San
Diego, CA), without analyzing the supernatant '

" . Another epithelial-based target

from the EPS urine sediment is the TMPRSS2-ERG fusion transcript which has been
shown to positively correlate with prostate cancer74'134'2U.
EPS fluids have yet to gain popularity for the detection and discovery of current
and new protein-based prostate cancer biomarkers. We hypothesize that EPS fluids are
an enriched source of prostate derived proteins like PSA and PAP, and therefore can be
useful for development of subsequent assays involving these two biomarkers. The
objective of this aim is to determine how readily detectable PSA and PAP are in EPS
fluids, and to determine if these fluids can be used in proteomic and glycomic based
experiments. We found through fractionation, gel-separation, and mass spectrometry
technologies that EPS fluids are indeed an enriched source of both PSA and PAP and
have great potential for discovery, validation, and clinical collection for future early
prostate carcinoma detection assays.

5.2 Experimental
Expressed prostatic secretions and urine samples
Urine samples, EPS urine samples, and direct EPS samples were acquired from
the Virginia Prostate Center (VPC) Biorepository, with EPS sample collection beginning
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in January 2007. Individuals providing the EPS urines are men who are scheduled for a
prostate biopsy at the clinic and have consented to having additional samples collected
for research purposes. When patients also provide a non-EPS urine sample, the voided
urine is collected one hour prior to the DRE. EPS urines are collected following the DRE
(10-20 ml), and are stored on ice for less than one hour at the clinic prior to transport to
the biorepository. Once at the biorepository the samples are centrifuged to remove the
cellular sediment, aliquoted, and all fractions and aliquots are stored at -80°C.
Two samples were collected from one individual on the same day. The first
sample was collected prior to the DRE, and was noted as "pre-DRE urine." The second
sample was collected following a routine DRE, and was termed "post-DRE urine" or
"EPS urine." Approximately two milliliters were obtained of each sample, and protein
concentrations were determined prior to any analysis. These samples were used for 20PAGE and LC-ESI-MS/MS analyses.
A single direct EPS sample was collected from a patient prior to a radical
prostatectomy. The collection of this sample involves a vigorous massage of the prostate
gland while the patient is under anesthesia during the pre-surgery exam, resulting in the
collection of pure prostatic secretions via the urethra (0.5-1 ml). The sample is then
stabilized in a sterile saline solution prior to centrifugation to obtain the cellular
sediments and subsequently aliquoted and stored at -80°C.
In addition to individual sample analysis, pools of samples were generated, based on
clinical diagnoses. An initial set of five pools were created based on the following
disease risk stratification: normal, BPH, low PCa, intermediate PCa, and high PCa (Table
1). Each pool comprised of six individual EPS urines; four milliliters per individual, for
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a total volume of 24 milliliters. The individual samples were first subjected to a lowspeed centrifugation (RT, 5K RPM, five minutes) to remove any additional contaminants
prior to pooling. The pools were concentrated using Amicon Ultra centrifugal filter
devices with a 10 kDa cut-off (Millipore, Carrigtwohill, Co. Cork, Ireland) and low-speed
centrifugation (4°C, 4.5K RPM, approximately 1 hour), resulting in a final volume of
approximately two milliliters per pool. Protein concentrations were determined for each
enriched pool. These pools were used for ID-PAGE, 2D-PAGE, western blotting, and
2DE western blotting.
A second set of EPS urine pools were created based on the following
stratifications BPH, low PCa risk, high PCa risk, and metastatic PCa (Table 1). Four
milliliters each of six samples were combined to create each EPS urine pool. These pools
were generated following the same protocol as for the above set of pools, with a final
volume of approximately two milliliters, and protein concentrations were also obtained.
This subset of pools was used for TAC, ID-PAGE, and western blot analyses.

Two-dimensional PAGE
Two-dimensional PAGE was performed following the manufacturer's protocol (BioRad
Laboratories Inc, Hercules, CA). Briefly, protein mixtures were combined with a
rehydration buffer, applied to an IEF strip (11cm, pH 3-10), and passively rehydrated at
room temperature overnight. The strips were then applied to the first dimension in a
BioRad IEF focusing unit, followed by two equilibration steps and the second
dimensional SDS-PAGE. For gels undergoing 2D-PAGE alone, the gels were either
silver stained or Coomassie blue stained. For 2DE western blotting, the gels were then
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transferred to PVDF membrane and processed following a standard western blotting
protocol. Two hundred micrograms of each EPS urine pool (normal, BPH, low PCa,
intermediate PCa, high PCa) was albumin and IgG depleted using commercially available
spin columns (Sigma) following the manufacture's protocol and precipitated (10% TCA)
prior to 2DE analysis and silver staining. Additionally, thirty micrograms per pool were
combined together for a total protein concentration of 150 micrograms; in duplicate.
These two pools were albumin and IgG depleted (ProteoPrep® Immunoaffinity albumin
and IgG Depletion Kit, Sigma-Aldrich, St. Louis, MO) and 10% TCA precipitated prior
to 2-DE analysis. One gel was silver stained while the mirror gel was transferred to
PVDF for western blotting.

Western blotting
Western blotting for the detection of both PSA and PAP was performed following
a standard western blot protocol. Briefly, gel-separated proteins were transferred to
PVDF membrane using a semi-dry transfer element (BioRad Laboratories Inc, Hercules,
CA). Blots were blocked with 5% milk in tris-buffered saline (TBS) for one hour
followed by an overnight incubation in primary antibody. For PSA, a primary antibody
was applied at a 1:3000 dilution in a 5% milk-TBS solution (goat anti-PSA affinity
purified, Biodesign International, Saco, ME). For PAP, a primary antibody generated by
our laboratory (mouse anti-PAP, protein A purified) was applied at a 1:1000 dilution in a
5% milk-TBS solution. After removal of the primary antibody, blots were washed before
addition of secondary antibodies (for PSA used 1:50,000 dilution of anti-goat IgG-HRP;
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for PAP used 1:5000 dilution of donkey anti-mouse IgG-HRP, Santa Cruz
Biotechnology). After one hour incubation with secondary antibody, the blots were
washed and a chemiluminescent buffer system was added to the blot for protein detection
(Immun-Star HRP, BioRad Laboratories Inc, Hercules, CA).

Enzyme-linked immunosorbent assay (ELISA)
An ELISA assay was performed following a protocol previously reported by
Alexander et al212. Briefly, 50 microliters of EPS urines were diluted 1:1 in coating
buffer (10 mM NaCl/50 mM NaP04, pH 7.5) and incubated overnight at 4°C in 96-well
plates. The plate wells were next blocked with the same coating buffer and 0.5% bovine
serum albumin, followed by an overnight incubation at 4°C with rabbit polyclonal
primary antibodies for PSA (1:500 dilution) or PAP (1:1000 dilution) (Abeam Inc,
Cambridge, MA). Finally, enzyme activity was detected using a secondary antibody
conjugated peroxidase assay (BioRad Laboratories Inc, Hercules, CA). Commercially
available purified standards from seminal fluids (Fitzgerald Industries, Concord, MA)
were used to generate linear standard curves for both PSA and PAP.

Thiophilic adsorption chromatography (TAC)
Thiophilic adsorption chromatography (TAC) was performed as previously
described in Chapter IV with minor modifications to optimize the protocol for this
physiologically different fluid. Briefly, 0.75 milligrams of total protein per pool (BPH,
low PCa risk, high PCa risk, metastatic PCa) was loaded onto each column with a total
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volume of three milliliters (sample and column buffer). Approximately four milliliters
was collected for each unbound fraction, and two milliliters for each subsequent fraction.

LC-ESI-MS/MS
Three individual samples ("pre-DRE urine", "post-DRE EPS urine", and "direct
EPS") were trypsin digested and analyzed for protein content using an LTQ™ Linear Ion
Trap (ThermoFinnigan, San Jose, CA). Ten micrograms of each sample was acetone
precipitated and the pellets were reconstituted in ten microliters of 25 raM ammonium
bicarbonate prior to digestion with paramagnetic immobilized trypsin beads
(EnzyBeads™ Trypsine, Agro-Bio, La Ferte Saint Aubin, France) following a protocol
developed by our laboratory. Briefly, samples were reduced by adding 100 mM of DTT
to each sample and incubating them at 56°C for one hour. After samples cooled to room
temperature, samples were alkylated in the dark for twenty minutes using 100 mM
iodoacetamide. While samples alkylate, 25 ul of trypsin beads were washed three times
with 25 mM ammonium bicarbonate. The wash buffer was removed from the beads, and
ten microliters of sample was added to the beads and mixed thoroughly. The bead and
sample mixture was incubated at 37°C for thirty minutes. The reaction was quenched by
removing the sample from the beads (using a magnetic separator) and placing the sample
in a new vessel. Two microliters of each sample was then used for LTQ analysis.
Digests were resuspended in 20 jxl Buffer A (5% acetonitrile, 0.1% formic acid, 0.005%
heptafluorobutyric acid) and 10 ul were loaded onto a 12-cm x 0.075 mm fused silica
capillary column packed with 5 uM diameter C-18 beads (The Nest Group,
Southborough, MA) using a N2 pressure vessel at 1100 psi. Peptides were eluted over
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300 minutes, by applying a 0-80% linear gradient of Buffer B (95% Acetonitrile, 0.1%
Formic Acid, 0.005% HFBA) at a flow rate of 150 ul/min with a pre-column flow splitter
resulting in a final flow rate of-200 nl/min directly into the source. A LTQ™ Linear Ion
Trap (ThermoFinnigan, San Jose, CA) was run in an automated collection mode with an
instrument method composed of a single segment and 5 data-dependent scan events with
a full MS scan followed by 4 MS/MS scans of the highest intensity ions. Normalized
collision energy was set at 28%, activation Q was 0.250 with minimum full scan signal
intensity at 1 x 105with no minimum MS2 intensity specified. Dynamic exclusion was
turned on utilizing a three minute repeat count of 2 with the mass width set at 1.0 m/z.
Protein searches were performed with MASCOT version 2.2.0 v (Matrix Sciences,
London GB) using the SwissProt version 51.3 database. Parent ion mass tolerance was
set at 1.5 and MS/MS tolerance 0.5 Da.

5.3 Results
2-D PAGE analysis of matched urine and EPS fluids
A matched set of urine samples were collected from one patient in the clinic, with
one sample being collected prior to the DRE exam and the other sample being collected
following the DRE exam. Seven hundred microliters of each sample was acetone
precipitated, the proteins were separated by 2D-PAGE and the gels were silver stained.
These gels were compared to one another to look for differences in protein patterns
among the two samples, specifically in the mass ranges where we expect to find PSA (32
kDa) and PAP (50 kDa). There are clear differences in spot patterns all over the gel as
well as in the mass ranges we expect to PSA and PAP (Figure 15).
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Figure 15. Comparison of pre-DRE urine to post-DRE urine. A matched set of urine
samples were collected from one patient in the clinic, with one sample being collected
prior to the DRE exam (panel A) and the other sample being collected following the DRE
exam (panel B). Each sample was acetone precipitated, the proteins were separated by
2D-PAGE, and the gels were silver stained.
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LC-ESI-MS/MS analysis of protein content of matched urine and EPS fluids
Ten micrograms of precipitated protein from the above matched samples was
trypsin digested and run on the LTQ instrument in order to analyze the total protein
content. The samples were first reduced and alkylated before being proteolytically
digested using trypsin bound to magnetic beads. The tryptic peptides were run against
the standard peptide identification gradient and the resultant spectrum were searched by
MASCOT for identification of proteins. For the pre-DRE urine sample, PSA and PAP
are not on the list of 45 significantly identified proteins, whereas for the post-DRE EPS
urine sample, 65 proteins were significantly identified, with PSA and PAP being in the
top 10 significant hits (Table 5 and Table 6). For the single direct EPS sample analyzed,
10 micrograms of protein was trypsin digested, and the digested peptides were also run
on the LTQ instrument and analyzed for protein content. MASCOT searches identified
74 significant proteins, with PSA and PAP being among the top 20 significant hits (Table
7).

TAC fractionation of EPS fluids and detection of PSA and PAP by western blot
The subset of pools containing disease stratifications BPH, low PCa, high PCa,
and metastatic PCa were TAC fractionated as described in the experimental section. A
lOOul aliquot of each elutedfractionwas 10% TCA precipitated in duplicate, the proteins
were separated by ID-PAGE, and the gels were subsequently either silver stained or
transferred to PVDF for western blot analysis. Figure 16 shows the resulting ID-PAGE
gels for each disease condition. PAP was found to elute in the unbound fraction,
therefore not binding to the TAC resin. PSA was found to elute acrossfractions2, 3, and

81
Table 5. Proteins identified in pre-DRE urine
Proteins significantly identified

emPAI score

peptide matches

1

Serum albumin

27.13

138

2

Uromodulin

2.66

82

3

Osteopontin

2.04

14

4

Prothrombin

0.44

14

5

Ig kappa chain C region

6.80

11

6

Kininogen-1

0.50

15

7

Vasorin

0.22

7

8

Protein AMBP

0.32

5

9

Serotransferrin

0.15

9

10

CD59 glycoprotein

2.38

7

11

Insulin-like growth factor-binding protein 7

0.63

8

12

Ig alpha-1 chain C region

0.33

11

13

Ribonuclease pancreatic

0.22

4

14

Clusterin

0.23

5

15

Ig lambda chain C regions

2.38

5

16

Pro-epidermal growth factor

0.18

11

17

Polymeric immunoglobulin receptor

0.04

7

18

Actin, alpha skeletal muscle

0.09

7

19

Actin, alpha cardiac muscle

0.09

5

20

Actin, cytoplasmic 1

0.09

4

21

ANKRD26-like family C member 1A

0.03

5

22

ANKRD26-like family C member IB

0.03

5

23

Inter-alpha-trypsin inhibitor heavy chain H4

0.07

4

24

Ig gamma-2 chain C region

0.35

5

25

Cubilin

0.01

6

26

Alpha-2-HS-glycoprotein

0.31

6

27

L-lactate dehydrogenase B chain

0.10

2

28

Lysosomal alpha-glucosidase

0.07

3

29

Attractin

0.02

9

30

Urokinase-type plasminogen activator

0.08

1

31

Mannan-binding lectin serine protease 2

0.05

3

32

Golgi membrane protein 1

0.17

3

33

Immunoglobulin J chain

0.25

1

34

Vitamin D-binding protein

0.07

1

35

Ubiquitin conjugation factor E4 B

N/A

5

36

CD44 antigen

0.05

3

37

Ig gamma-1 chain C region

0.10

4
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38

Sperm flagellar protein 2

N/A

7

39

Beta-2-microglobulin

0.29

1

40

Bone morphogenetic protein receptor type-IB

N/A

4

41

Vitronectin

0.07

2

42

GPN-loop GTPase 1

0.09

1

43

Ciliary neurotrophic factor receptor alpha

0.09

2

44

Mitochondrial GTPase 1

0.10

2

45

Transcription factor BTF3 homolog 3

0.16

2

Two micrograms of reduced, alkylated and trypsin digested peptides were applied to an
LTQ™ Linear Ion Trap (ThermoFinnigan) mass spectrometer in the data-dependent
acquisition mode for mass spectrometry analysis. Survey full scan MS spectra (m/z 300
to 1800) were acquired, with the four most intense ions in a scan sequentially isolated and
fragmented in the linear ion trap by MS/MS. The peptide sequences were identified from
their tandem mass spectra using Mascot in conjunction with the SwissProt database, and
by using the following search criteria: carbamido-methylation of cysteine and oxidation
of methionine residues as variable modifications, 1 missed enzyme cleavage site, and an
error tolerance of 1.5 Da for MS and 0.5 Da for MS/MS.
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Table 6. Proteins identified in post-DRE "EPS" urine
emPAI score

peptide matches

1

Proteins significantly identified
Serum albumin

18.53

109

2

Lactotransferrin

3.21

50

3

Uromodulin

1.97

49

4

Prostatic acid phosphatase

2.36

41

5

Ig kappa chain C region

13.02

16

6

Ig alpha-1 chain C region

0.61

9

7

Prostate-specific antigen

2.05

12

8

Alpha-2-HS-glycoprotein

0.58

7

9

Polymeric immunoglobulin receptor

0.19

9

10

Prothrombin

0.23

8

11

Osteopontin

0.22

6

12

Transmembrane protease, serine 2

0.14

3

13

Collagen alpha-1 (VI) chain

0.03

5

14

IgGFc-binding protein

0.01

8

15

Protein AMBP

0.44

7

16

Annexin Al

0.20

2

17

Brain acid soluble protein 1

0.17

3

18

Ig gamma-1 chain C region

0.49

4

19

Serotransferrin

0.05

6

20

Amyloid beta A4 protein

0.04

3

21

Ig gamma-2 chain C region

0.35

3

22

Vasorin

0.11

2

23

Carboxypeptidase E

0.15

4

24

Plasma protease CI inhibitor

0.22

7

25

CD9 antigen

0.32

3

26

Myeloperoxidase

0.04

3

27

Kallikrein-2

0.28

4

28

Complement C3

0.04

7

29

Lysosomal alpha-glucosidase

0.04

4

30

CD59 glycoprotein

1.08

4

31

Vitamin D-binding protein

0.07

2

32

Haptoglobin-related protein

0.10

2

33

Leucine-rich repeat-containing protein 47

0.06

2

34

Heat shock protein HSP 90-alpha

0.04

4

35

Ribonuclease pancreatic

0.22

2

36

Ig heavy chain V-III region GA

0.30

1

Isocitrate dehydrogenase [NADP1 cytoplasmic

0.08

3

37
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38

Metallothionein-1 G

0.70

4

39

Metallothionein-1M

0.70

3

40

Metallothionein-IE

0.71

4

41

Metallothionein-2

0.71

2

42

Receptor-type tyrosine-protein phosphatase eta

0.03

3

43

Aminopeptidase N

0.07

4

44

Ig heavy chain V-III region WEA

N/A

1

45

Non-secretory ribonuclease

0.21

2

46

Talin-1

0.01

7

47

Ras-related protein R-Ras2

0.16

3

48

L-xylulose reductase

0.15

3

49

Peptidyl-prolyl cis-trans isomerase A

0.21

2

50

Heat shock 70 kDa protein 1

0.11

2

51

Tetraspanin-6

0.14

2

52

Collagen alpha-1 (XV) chain

0.03

2

53

14-3-3 protein theta

0.14

2

54

Heat shock 70 kDa protein 6

0.05

2

55

Heat shock 70 kDa protein 1L

0.05

3

56

Heat shock cognate 71 kDa protein

0.05

2

57

RNA-binding protein 28

0.04

2

58

Protein GRINL1A

N/A

2

59

Cofilin-1

0.21

1

60

Deoxyribonuclease-2-alpha

0.09

1

61

Alpha-enolase

0.08

1

62

Ryanodine receptor 2

0.01

10

63

Splicing factor 3B subunit 1

N/A

1

64

Syndecan-4

0.18

2

65

Serine/threonine-protein kinase SMG1

0.01

10

Two micrograms of reduced, alkylated and trypsin digested peptides were applied to an
LTQ™ Linear Ion Trap (ThermoFinnigan) mass spectrometer in the data-dependent
acquisition mode for mass spectrometry analysis. Survey full scan MS spectra (m/z 300
to 1800) were acquired, with the four most intense ions in a scan sequentially isolated and
fragmented in the linear ion trap by MS/MS. The peptide sequences were identified from
their tandem mass spectra using Mascot in conjunction with the SwissProt database, and
by using the following search criteria: carbarnido-methylation of cysteine and oxidation
of methionine residues as variable modifications, 1 missed enzyme cleavage site, and an
error tolerance of 1.5 Da for MS and 0.5 Da for MS/MS.
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Table 7. Proteins identified in direct EPS fluids
Proteins significantly identified

emPAI score

peptide matches

1

Protein-glutamine gamma-glutamyltransferase 4

1.94

33

2

Serum albumin

3.04

54

3

Brain acid soluble protein 1

2.32

11

4

Lactotransferrin

0.43

9

5

Ig kappa chain C region

0.46

2

6

Aminopeptidase N

0.29

9

7

Zinc-alpha-2-glycoprotein

1.57

13

8

Creatine kinase B-type

0.71

19

9

Actin, cytoplasmic 1

0.55

9

10

Prostate-specific antigen

1.21

13

11

Phosphatidylethanolamine-binding protein 1

0.24

2

12

Neprilysin

0.11

4

13

Prostatic acid phosphatase

0.86

10

14

Myristoylated alanine-rich C-kinase substrate

0.34

3

15

Ig alpha-1 chain C region

0.44

8

16

Cytochrome b561

0.39

2

17

Semenogelin-2

0.15

5

18

Actin, aortic smooth muscle

0.24

7

19

ANKRD26-like family C member 1A

0.08

11

20

2

Transmembrane BAX inhibitor motif-containing protein 1

0.14

21

Isocitrate dehydrogenase [NADP1 cytoplasmic

0.34

5

22

Serotransferrin

0.13

5

23

Ig kappa chain V-III region SIE

0.46

2

24

Galectin-3-binding protein

0.07

3

25

Heat shock protein HSP 90-beta

0.12

3

26

Peptidyl-prolyl cis-trans isomerase A

0.28

2

27

Putative zinc-alpha-2-glycoprotein-like 1

0.48

3

28

Ig gamma-1 chain C region

0.66

6

29

Ig lambda chain C regions

0.48

3

30

Semenogelin-1

0.30

6

31

Ig gamma-4 chain C region

0.29

3

32

Macrophage migration inhibitory factor

1.04

2

33

Kappa-actin

0.12

7

34

Beta-actin-like protein 2

0.12

6

35

Putative heat shock protein HSP 90-beta 4

0.08

9

36

Heat shock protein HSP 90-alpha

0.06

3
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37

Endoplasmin

0.05

5

38

Transthyretin

0.33

2

39

Ig gamma-2 chain C region

0.14

5

40

Receptor-type tyrosine-protein phosphatase S

0.02

9

41

Dipeptidyl peptidase 4

0.11

2

42

IgGFc-binding protein

0.01

11

43

Polymeric immunoglobulin receptor

0.06

4

44

Annexin A5

0.14

3

45

Ras-related protein Rab-4A

N/A

3

46

Ras-related protein Rab-8B

N/A

3

47

Ras-related protein Rab-39B

N/A

2

48

Ras-related protein Rab-30

N/A

2

49

Ras-related protein Rab-15

0.20

5

50

Ras-related protein Rab-35

N/A

2

51

Ras-related protein Rab-3B

N/A

2

52

Ras-related protein Rab-6A

N/A

3

53

Ras-related protein Rab-3C

N/A

4

54

Ras-related protein Rab-37

N/A

4

55

Ras-related protein Rab-3A

N/A

2

56

Ras-related protein Rab-1 A

N/A

2

57

Ras-related protein Rab-33B

N/A

1

58

Calcineurin subunit B type 1

0.26

5

59

Glycogen phosphorylase, brain form

0.05

1

60

Ras-related protein Rab-27A

0.20

2

61

Annexin A3

0.13

2

62

Heat shock 70 kDa protein 1

0.07

4

63

Prostasin

0.29

4

64

Apoptosis-inducing factor 2

N/A

3

65

Structural maintenance of chromosomes protein 5

N/A

7

66

Protein S100-A8

0.50

2

67

Zinc finger protein ZXDC

N/A

3

68

Nephrocystin-3

0.03

9

69

Fatty acid synthase

0.02

3

70

Synaptotagmin-like protein 5

N/A

5

71

RalBPl-associated Eps domain-containing protein 2

N/A

3

72

BUD 13 homolog

N/A

7

73

Myosin-Ixb

N/A

4

74

Paraneoplastic antigen Ma2

0.12

5
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Two micrograms of reduced, alkylated and trypsin digested peptides were applied to an
LTQ™ Linear Ion Trap (ThermoFinnigan) mass spectrometer in the data-dependent
acquisition mode for mass spectrometry analysis. Survey full scan MS spectra (m/z 300
to 1800) were acquired, with the four most intense ions in a scan sequentially isolated and
fragmented in the linear ion trap by MS/MS. The peptide sequences were identified from
their tandem mass spectra using Mascot in conjunction with the SwissProt database, and
by using the following search criteria: carbamido-methylation of cysteine and oxidation
of methionine residues as variable modifications, 1 missed enzyme cleavage site, and an
error tolerance of 1.5 Da for MS and 0.5 Da for MS/MS.
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Figure 16. 1D-PAGE analysis of TAC fractionated EPS urine samples. Thiophilic
adsorption chromatography (TAC) was used to fractionate pooled EPS urine fluids. The
collected fractions were then run on 12% Bis-Tris gels, and silver stained. The diseasedefined pools fractionated were BPH (Panel A), low risk PCa (Panel B), high risk PCa
(Panel C), and metastatic PCa (Panel D). Lane 1 contains proteins that did not bind the
TAC resin, with subsequent sodium sulfate elutions in Lane 2 (0.8M), Lane 3 (0.6M),
Lane 4 (0.4M), Lane 5 (0.2M), and Lane 6 (O.OM). PSA and PAP were detected in
respective fractions by gel staining and western blotting.
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four which represent 0.6M, 0.4M, and 0.2M sodium sulfate elution fractions respectively,
with the majority of PSA being detected in the 0.4M fraction (Figure 16).

2-DE western blot analysis for PSA and PAP from EPS fluids
A large pool of a subset of EPS urine pools (normal, BPH, low PCa risk,
intermediate PCa risk, and high PCa risk) was created to examine the feasibility of
detecting PSA and PAP in these fluids. In order to better examine the isoforms of both
PSA and PAP, western blot analysis was performed on 2D-PAGE separated proteins.
The total 150 ug of protein (in duplicate) was first albumin and IgG depleted using spin
columns and then 10% TCA precipitated prior to 2D-PAGE analysis of mirror gels. One
gel was silver stained for total protein content examination, while the second gel was
transferred to PVDF membrane for western blotting. The blot was first probed and
detected for PAP, then stripped of the primary and secondary antibodies as well as the
ECL reagents (Restore western blot stripping buffer, Pierce-Thermo Fisher Scientific Inc,
Rockford, IL), followed by probing for and detection of PSA. Figure 17 illustrates the
2D-PAGE map of all proteins detected by silver staining from EPS urines, as well as the
2D-PAGE pattern for both PSA and PAP isoforms and glycoforms in these EPS urine
fluids213.

ELISA analysis of PSA and PAP concentrations in EPS fluids
ELISA assays were performed in order to examine the levels of PSA and PAP
present in the EPS samples used in the aforementioned experiments. We found that for
the majority of EPS urines there is a detection range of 10-40 ug/ml for PSA and 3-10
ug/ml for PAP. Additionally, we observed a range of 80-120 ug/ml for PSA and 20-40
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Figure 17. 2D-PAGE western blot analysis of PSA and PAP in EPS urine samples.
Five disease-defined pools (normal, BPH, low risk PCA, intermediate risk PCa, high risk
PCa) of EPS urines were combined together to make a general EPS urine pool unrelated
to disease state and used for 2D-PAGE immunoblotting for the detection of both PSA and
PAP. Two identical 8-16% Criterion Tris-HCl gels (BioRad) were run concurrently
following the first dimension separation of EPS urine proteins. Following the gel
electrophoresis, one gel was silver stained, while the second gel was transferred to PVDF
membrane and western blot analysis was performed for both PSA and PAP. The silver
stained gel and the PSA and PAP western blots are shown above with PAP and PSA
spots highlighted on the silver stained gel. Adapted from Drake et al., 2009.
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ug/ml for PAP in direct EPS fluids derived from cancer patients. Figure 18 illustrates the
PSA and PAP levels across non-cancer (normal and BPH) and prostate cancer disease
states (low risk, intermediate risk, high risk) in EPS urines. Lower levels of both PSA
and PAP are observed in the prostate cancer EPS fluids as compared to the non-cancer
samples.

5.4 Discussion
EPS fluids have routinely been collected in the clinic for the detection of
prostatitis and chronic pelvic inflammatory disease, and the epithelial cell pellets
resulting from these fluids are being used in a number of genetic-based assays for
prostate cancer detection74'132"134,206-210 Proteomic profiling of other bodily fluids such
as seminal fluid and urine have been conducted '

, however with no published studies

to date, other than ours213, involving protein analysis of the EPS fluids, our current
analyses are novel and therefore are capable of providing the field with a wealth of new
knowledge. With our present studies, we have determined that post-DRE "EPS" urines
are an enriched source of prostate-derived proteins (Table 6), with PSA and PAP being
the most important targets for this dissertation.
We have observed a clear difference in protein content between urine and EPS
urines collected from the same patient within the same day, with a detectable presence of
prostate-related proteins in the post-DRE urines as compared to the pre-DRE urines. This
has been demonstrated by both 2D-PAGE analysis and LC-ESI mass spectrometry
analysis of the pre-DRE and post-DRE urine collections (Figure 15, Table 5, and
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Figure 18. Concentration of PSA and PAP in EPS urines. ELISA assays were used
to assess the concentrations of PSA (A) and PAP (B) in non-cancer (normal and BPH)
and cancer (low risk, intermediate risk, and high risk) EPS urines, with the results
displayed in the above box plots. The EPS urines were combined 1:1 with coating buffer
(10 mM NaCl/50 mM NaP04, pH 7.5), and incubated overnight at 4°C in 96-well plates.
On the next day, the wells were blocked with 0.5% bovine serum albumin in coating
buffer; followed by an overnight incubation with primary antibody at 4°C. Finally,
secondary antibodies conjugated to peroxidase allowed for detection of the enzyme
activity on the next day. The above diagram plots the mean, 10th, 25th, 75th and 90th
percentiles as vertical boxes with error bars, with outlier samples shown as dots outside
of the box. Adapted from Drake et al., 2009.
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Table 6). These analyses indicate a relative increase in protein abundance in the postDRE urine as compared to the pre-DRE urine based on the spot patterns observed in the
2D- PAGE gels and the increase in numbers of proteins identified by mass spectrometry.
In addition, we have found that both PSA and PAP are among the top most significant
proteins identified in both EPS urine and direct EPS fluids (Table 5, Table 6, and Table
7) based on the LC-ESI mass spectrometry analysis. Additionally, we have successfully
fractionated EPS urines by thiophilic adsorption chromatography, and have identified
both PSA and PAP in their respective fractions (Figure 16). This fractionation scheme
provides us with partially purified forms of PSA and PAP which can be further gelpurified and used in subsequent mass spectrometry-based assays for both protein and
carbohydrate analyses. In addition, we have also effectively used 2D-PAGE western blot
analysis to detect individual isoforms of both PSA and PAP derived from EPS urines
(Figure 17). These isoforms likely indicate various glycoforms of PSA and PAP,
therefore providing us with the ability to use these fluids to identify and target individual
glycoforms for both proteins, which may be indicative of various prostate disease states,
such as BPH and cancer. Finally, we used ELISA assays to examine the concentration of
PSA and PAP in EPS fluids (Figure 18). We observed that there are decreased levels of
both PSA and PAP in the cancer samples as compared to the non-cancer samples, which
correlate with increased PSA and PAP levels seen in blood of some cancer patients. For
the EPS urine samples used the non-cancer group had an average serum PSA level of 4.6
ng/ml (+/- 2.0; range 0.7- 7.9), and the cancer group had an average serum PSA level of
6.8 ng/ml (+/-5.0; range 0.1-24.5). It is likely that we are seeing lower protein levels
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derived from the prostate as these proteins are leaked into the blood stream in some
prostate cancer states.
All of these abovementioned characteristics will allow us to use these types of
prostatic fluids in more targeted glycoproteomic and glycomic studies, with the intention
of discovering superior biomarkers for the early diagnosis of prostate carcinomas. While
direct EPS fluids are a great discovery fluid, they are not readily obtained in the clinic
during a routine physical exam, as these fluids are collected under anesthesia prior to
radical prostatectomy. However, EPS urines are useful as a discovery tool and are easily
collected in the clinic during a routine physical exam, therefore making EPS urine fluids
relevant for validation and use in clinical assays for the detection of early prostate
carcinomas in the near future.
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CHAPTER V
AIM III: APPLICATION OF NEW METHODOLOGIES TO EXPRESSED
PROSTATIC SECRETIONS FOR PROSTATE CANCER GLYCOPROTEIN
BIOMARKER DISCOVERY

6.1 Introduction
As previously stated, EPS fluids are proximal to the prostate and therefore are an
enriched source of potential biomarkers for the detection of early prostate cancer. We
have also demonstrated in aim II the enriched presence of prostate-derived proteins in
post-DRE urines as compared to pre-DRE urines (Table 5 and Table 6). While geneticbased tests are already on the market74' 132-134>206-2105 the use of EPS fluids for proteomic
analyses and assays is not widely observed. In addition to potential protein biomarkers,
the carbohydrate structures attached to glycoproteins may also provide the diagnostic
information needed for better disease biomarkers. We hypothesize that by performing
initial glycomic and glycoproteomic studies using EPS samples we will build the
foundation for more targeted biomarker studies with the focus on the carbohydrate
structures attached to secreted glycoproteins. As PSA and PAP are two prominent
prostate-derived proteins, they make ideal targets for glycoproteomic and glycomic
studies.
In addition to these two specific targets, total glycan approaches also have great
utility in glycomic studies. First, the total glycan profile for a given fluid across differing
disease states, such as cancer versus non-cancer, may provide a panel of altered
glycoforms that can be used diagnostically for the detection of a given disease state, such
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as prostate cancer. Secondly, once candidate glycoforms are identified, it may be
possible to determine which proteins these glycoforms are attached to, allowing for the
subsequent generation of protein-based biomarker clinical assays. The objective of this
aim is to examine the glycosylation state of both PSA and PAP in EPS urine samples, as
well as to examine the total glycan constituents in EPS urine and direct EPS samples.
These goals will be achieved by first obtaining cleaved glycans from PSA and PAP
derived from EPS urine samples, permethylating the free structures, and analyzing them
by MALDI-TOF mass spectrometry. Next, we will use EPS urine-derived PAP in
glycopeptide analyses using a triple quadruple mass spectrometer in precursor ion
scanning mode with the intent to identify individual glycoforms at each N-linked
glycosylation site of PAP. And finally, we will obtain a fraction of cleaved glycans from
EPS urine and direct EPS pools, permethylate these structures and analyze them by
MALDI-TOF/TOF. We have determined that EPS urine-derived PAP glycans have a
great potential in providing glycomic targets for better clinical assays. Additionally, total
glycan profiles of EPS urine and direct EPS fluids may also provide valuable diagnostic
glycan-based biomarkers for the detection of early prostate carcinomas.

6.2 Experimental
Expressed prostatic secretion samples
EPS urine and direct EPS samples were acquired from the Virginia Prostate
Center (VPC) Biorepository, with EPS sample collection beginning in January 2007.
Individuals providing the EPS urines are men who are scheduled for a prostate biopsy at
the clinic and have consented to having additional samples collected for research
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purposes. When patients also provide a non-EPS urine sample, the voided urine is
collected one hour prior to the DRE. EPS urines are collected following the DRE (10-20
ml), and are stored on ice for less than one hour at the clinic prior to transport to the
biorepository. Once at the biorepository the samples are centrifuged to remove the
cellular sediment, aliquoted, and all fractions and aliquots are stored at -80°C.
Direct EPS samples were collected from patients prior to a radical prostatectomy.
The collection of this sample involves a vigorous massage of the prostate gland while the
patient is under anesthesia during the pre-surgery exam, resulting in the collection of pure
prostatic secretions via the urethra (0.5-1 ml). The sample is then stabilized in a sterile
saline solution prior to centrifugation to obtain the cellular sediments and subsequently
aliquoted and stored at -80°C.
Pools of EPS urine and direct EPS samples were generated based on clinical
diagnoses. The set of five pools that were previously described in chapter V and were
created based on the following disease risk stratification: normal, BPH, low PCa,
intermediate PCa, and high PCa, were used for total glycan analyses of EPS urine fluids
(Table 1). Each pool comprised of six individual EPS urines; four milliliters per
individual, for a total volume of 24 milliliters. The individual samples were first
subjected to a low-speed centrifugation (RT, 5K RPM, five minutes) to remove any
additional contaminants prior to pooling. The pools were concentrated using Amicon
Ultra centrifugal filter devices with a 10 kDa cut-off (Millipore, Carrigtwohill, Co. Cork,
Ireland) and low-speed centrifugation (4°C, 4.5K RPM, approximately 1 hour), resulting
in a final volume of approximately two milliliters per pool.
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A set of three EPS urine pools were created based on the following disease risk
stratification: normal, BPH, and PCa. Each pool comprised often individual EPS urines;
four milliliters per individual, for a total volume of 40 milliliters. The individual samples
were first subjected to a low-speed centrifugation (RT, 5K RPM, five minutes) to remove
any additional contaminants prior to pooling. The pools were concentrated using Amicon
Ultra centrifugal filter devices with a 10 kDa cut-off (Millipore, Carrigtwohill, Co. Cork,
Ireland) and low-speed centrifugation (4°C, 4.5K RPM, approximately 1 hour), resulting
in a final volume of approximately two milliliters per pool. Protein concentrations were
determined for each enriched pool. These pools were used for ID-PAGE, western
blotting, TAC, glycan analyses, and glycopeptide analyses.
A set of direct EPS pools were created based on the following stratifications: low
risk PCa and intermediate risk PCa (Table 1). Four milliliters each of six samples were
combined to create each EPS urine pool. These pools were generated following the same
protocol as for the above sets of pools, with a final volume of approximately two
milliliters, and protein concentrations were also obtained. This set of pools was used for
total glycan analyses.

Thiophilic adsorption chromatography (TAC)
PSA and PAP were purified from a set EPS urine pools (normal, BPH, PCa) using
thiophilic adsorption chromatography (TAC) as previously described in chapter III with a
few adjustments based on the protein concentrations and volumes available for the new
pools. Briefly, 1.0 milligram of total protein per pool was loaded onto each column with
a total volume of four milliliters (sample and column buffer). Approximately four
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milliliters was collected for each unbound fraction, and two milliliters for each
subsequent fraction.

N-glycan permethylation
TAC-purified PSA and PAP gel bands derived from EPS urine pools were
permethylated195 following trypsin digestion as previously described in chapter III.
Briefly, gel bands were reduced and alkylated, and then tryptically digested at 37°C for
18 hours. Next, trypsin was denatured at 100°C for 5 minutes, and PNGase F (New
England Biolabs, Ipswich, MA) was added to the peptide mixture and incubated at 37°C
for 18 hours. The resulting sample was purified by CI8 columns and the N-glycans were
collected in 5% acetic acid, and subsequently dried under reduced pressure. Dried Nglycans were permethylated following the protocol described by Ciucanu and Kerek195.
The permethylated N-glycans were purified using CI8 columns, eluted in 85%
acetonitrile, and then dried under a nitrogen stream.
In addition to gel bands, total glycan analysis was performed on tryptic peptides
derived from EPS urine and direct EPS pools. Non-PCa and PCa sample sets were
created from previously described EPS urine pools. For direct EPS samples, low PCa
risk and intermediate PCa risk stratifications were used to generate the pooled sample
sets. Each pool to be permethylated consisted of 180 micrograms of protein, which was
subsequently precipitated prior to trypsin digestion, PNGase digestion, and
permethylation.

MALDI-TOF/TOF
The dried permethylated N-glycans were prepared and analyzed by MALDI-TOF
as previously described in chapter III. Briefly, the dried permethylated N-glycans were
reconstituted in 100% methanol, and the sample was mixed 1:1 with 2,5Dihydroxybenzoic acid (DHB) matrix (20mg/ml in 50% methanol), and then spotted on
the MALDI-TOF target plate. Each sample was analyzed in positive ion mode and
FlexControl and FlexAnalysis software (Bruker Daltonics, Germany) were used for
spectra processing. The MALDI-TOF LIFT cell was utilized for MS/MS fragmentation
analysis of permethylated glycans from total EPS pools. A glycan database offered by
the Consortium for Functional Glycomics (http://www.functionalglycomics.org) was
used to search permethylated glycan masses correlating to peaks of interest in MALDITOF spectra, and glycan "cartoons" representing mass peaks were built using
GlycanBuilder ver 1.2 build 3353196.

Hybrid triple quadrupole/linear ion trap mass spectrometry
A hybrid triple quadrupole/linear ion trap mass spectrometer 4000 (QTRAP®
LC/MS/MS system, Applied Biosystems, Foster City, CA) coupled to a Tempo NanoLC
system (Eksigent Technologies, Dublin, CA) was used to determine the structures of the
glycans attached to each of the three PAP linkage sites: Asn-62, Asn-188, and Asn-301.
The methods described by Sandra et al.197 were used with minor modifications to
optimize for our samples and instrumentation, and are detailed in chapter III. Figure 19
illustrates how the QTRAP was used in precursor ion scanning mode.
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Figure 19. Triple quadrupole ion trap configuration for precursor ion scanning.
Dried tryptic and chymotryptic peptides are reconstituted in 20 microliters of Buffer A
(5% acetonitrile/0.1% formic acid/0.005% heptafluorobutyric acid in water) and 8
microliters per experiment is injected into the nanoLC system for fractionation prior to
being applied to the nanospray ionization (NSI) source and trapped in quadrupole 0 (Q0).
Next, the peptides are scanned in quadrupole 1 (Ql) to determine their masses and
retention times. The peptides then travel to quadrupole 2 (Q2) which acts as a collision
cell where fragmentation of the parent ions occurs. The ions then reach Quadrupole 3
(Q3) which is set to transmit only the mass of the diagnostic oxonium ions to the
detector, such as m/z 163 (Hex+), 204 (HexNAc+), 292/274/256 (NeuAc+1), and 366
(HexHexNAc+). Upon their detection, an enhanced product ion scan (EPI) of the
precursor ion is triggered causing fragmentation of the selected parent ions in Q2, then
fragmented ions are captured in the ion trap and scanned out generating an MS/MS
spectrum containing ions from the both the peptide and the attached carbohydrate
structure. Additionally, the charge state of the parent ion will be reported, allowing for
complete annotation of the spectrum, as illustrated in Figure 13.

ClinProt computational data analysis
ClinProt software version 2.0 (Bruker Daltonics, Germany) was used to baseline
subtract, normalize spectra (using total ion current) and determine peak m/z values and
intensities in the mass range of 1,000 to 6,000 daltons for the EPS PAP and EPS urine
total glycan MALDI-TOF data. A mass window of 0.5% was used to align the spectra,
and a k-nearest neighbor genetic algorithm was used to identify statistically significant
differences in protein peaks in the three groups analyzed. Comparison of relative peak
intensity levels between groups was also calculated within the software suite.

6.3 Results
Purification of PSA and PAP from EPS urine pools
Pooled sample sets representative of normal, benign prostatic hyperplasia (BPH)
and prostate cancer conditions were generated using a biorepository of EPS urine
1 80

samples. Thiophilic adsorption chromatography (TAC)

was used to purify PSA and

PAP from the concentrated, pooled EPS urine fluids by batch elution. Approximately six
milliliters was collected as flow-through and labeled as the unbound fraction, while
approximately three milliliters was collected for each subsequent salt elution fraction.
The consequential protein fractions were separated by SDS-PAGE, and it was observed
that PAP did not bind to the TAC resin, while PSA eluted in the 0.6M, 0.4M, and 0.2M
sodium sulfate fractions (Figure 20). We detected both PSA and PAP by Coomassie blue
staining, and PSA and PAP identities were confirmed in their respective fractions by
western blotting.
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Figure 20. Thiophilic adsorption chromatography of EPS urine pools. EPS urine
protein fractions from normal, BPH, and PCa defined pools purified by thiophilic
adsorption chromatography (TAC) were separated on a 12% Bis-Tris NuPAGE SDS-gel
(Invitrogen) and silver stained. Proteins that did not bind the TAC resin are shown in the
lane marked Unbound, with protein from the 0.8M NaS04 elution, 0.6M, 0.4M, 0.2, and
0 M/25mM HEPES in the following lanes. PAP and PSA identities were confirmed in
the above fractions by staining and western blots.

MALDI-TOF analysis of permethylated PSA and PAP glycans from EPS urines
Permethylation195 of PNGase F cleaved glycans and MALDI-TOF analysis of the
derivatized structures was performed for each of the EPS urine clinically-defined groups
in order to further characterize PSA and PAP glycans. For PAP, 36 glycan structures
were positively identified by MALDI-TOF, with the majority of these being complex
sub-types, and a few representatives of the high-mannose sub-type were present as well
(Table 8). For some structures, the sub-type was not able to be determined; however
these structures would ultimately be classified as either a complex or hybrid subtype.
Figure 21 represents the MALDI-TOF spectra collected for the permethylated PAP
glycans from the normal, BPH, and PCa cohorts. Permethylated glycans cleaved from
PSA in these EPS urine sample pools were not as readily detectable as structures from
PAP, with only 23 structures being confidently identified (Table 9). The structures
detected were mostly of the complex and high-mannose sub-types, with these results
remaining consistent with glycan structures previously reported for PSA arising from
serum and seminal f l u i d s " J " ' " ' , as well as seen from our seminal plasma studies
(Table 3). MALDI-TOF spectra obtained for the PSA glycans for the EPS urine samples
is shown in Figure 21.

Triple-quadrupole mass spectrometry analysis of PAP glycopeptides derived from
EPS urines
As in aim I, glycopeptide analysis of the three N-linked glycosylation sites for
PAP found in EPS urine fluids was performed using a triple-quadrupole mass
spectrometer. PAP-containing EPS urine fractions were separated by SDS-PAGE and

Table 8. Permethylated PAP glycans from normal, BPH, and PCa EPS urine pools
analyzed by MALDI-TOF
Number

m/z

Proposed Glycan Structure
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•
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Identified m/z values were used for database searches, and corresponding masses that
could be assigned to a biologically relevant N-glycan structure are listed. An asterisk
denotes structures that are one representation of multiple possible glycoforms for a given
mass. The shown structure in these cases was chosen based on its apparent prevalence in
mammalian species. Cartoon representations are as follows:
• =GlcNAc, •
=Mannose, O =Galactose, A=Fucose, •=NeuAc, • =GalNAc
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Figure 21. MALDI-TOF spectra of permethylated PAP glycans derived from EPS
urine samples. Representative MALDI spectra for permethylated PAP glycans from
BPH, normal, and PCa disease-defined pools are shown. Glycan structures
corresponding to detected m/z peaks are listed in Table 8.

Table 9. Permethylated PSA glycans from normal, BPH, and PCa EPS urine pools
analyzed by MALDI-TOF
Number

Proposed Glycan Structure

m/z

*

1
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2
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Identified m/z values were used for database searches, and corresponding masses that
could be assigned to a biologically relevant N-glycan structure are listed. An asterisk
denotes structures that are one representation of multiple possible glycoforms for a given
mass. The shown structure in these cases was chosen based on its apparent prevalence in
mammalian species. Cartoon representations are as follows:
• =GlcNAc, #
=Mannose, O =Galactose, A=Fucose, ^=NeuAc, D=GalNAc
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Figure 22. MALDI-TOF spectra of permethylated PSA glycans derived from EPS
urine samples. Representative MALDI spectra for permethylated PSA glycans from
BPH, normal, and PCa disease-defined pools are shown. Glycan structures
corresponding to detected m/z peaks are listed in Table 9.

proteolytically digested with either trypsin or chymotrypsin prior to further sample
separation by the in-line nanoLC system and mass spectrometry analysis. Precursor ion
mode was utilized for the detection of oxonium ions 163, 292, and 366 as previously
described in chapter III. Figure 23 illustrates an identified chymotrypsin digested
glycopeptide with an attached high mannose glycan structure, while Figure 24
demonstrates a complex biantennary, singly sialylated N-glycan attached to a tryptic
glycopeptide. Overall, we identified two complex structures attached to Asn-62, and one
high mannose structure attached to Asn-301 (Table 10). These data correlate with our
previous studies using seminal plasma-derived PAP peptides, however we did not
successfully identify as many glycoforms attached to Asn-62 and Asn-301, nor did we
positively identify any glycoforms at Asn-188.

Total glycan analysis of EPS urine and direct EPS pools by MALDI-TOF
In order to further characterize EPS fluids, glycan analysis on total pools was
performed. A paired cohort or EPS urines deemed non-cancer and cancer were used as
representatives of EPS urine fluids. The non-cancer pool consisted of normal and BPH
classified individuals, while the cancer pool was generated from individuals with low,
intermediate, or high-risk diagnosed prostate cancer. Each pool contained a total of 180
micrograms of protein (90 micrograms each of normal and BPH; 60 micrograms each of
low, intermediate, and high risk PCa), and the pools were precipitated with 10% TCA
prior to trypsin digestion. For direct EPS samples, a pool of low-risk prostate cancer
individuals was compared to a pool containing intermediate-risk prostate cancer
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Figure 23. Precursor ion scan for 163 m/z hexose of chymotryptic EPS urine PAP
peptides. A) Enhanced Product Ion (EPI) scan of a quadrupole-charged PAP
glycopeptide with parent mass of 2929.35. B) Expanded window of above EPI scan
showing fragmentation of the parent ion that corresponds to the chymotryptic peptide
RNETQHEPYPLM containing the glycosylation site Asn-301 and a Man6 N-glycan.
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Figure 24. Precursor ion scan for 366 m/z hexose of tryptic EPS urine PAP
peptides. A) Enhanced Product Ion (EPI) scan of a quadrupole-charged PAP
glycopeptide with parent mass of 2816.31. B) Expanded window of above EPI scan
showing fragmentation of the parent ion that corresponds to the tryptic peptide
FLNESYK containing the glycosylation site Asn-62 and a complex biantennary, singly
sialylated N-glycan.
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Table 10. EPS urine PAP glycopeptides and their corresponding N-glycan
structures identified by triple quadrupole MS/MS analysis
N-linked Glycosylation site

Asn-62

Peptides generated by enzymatic digestion
Trypsin Digestion
FLNESYK 900.45
FLNESYKHEQVYIR 1825.9
KFLNESYKHEQVYIR 1954.0

Chymotrypsin Digestion

Structures Identified
•

- • • > • .
-.: • •
* '.• • -«^
• • •

RKFLNESYKHEQVY 1840.9

Trypsin Digestion
Asn-188

N/A

N/A

Chymotrypsin Digestion
N/A

Trypsin Digestion
NETQHEPYPLMLPGCSPSCPLER 2712.2

Asn-301

GEYFVEMYYRNETQHEPYPLMLPGCSPSCPLER 4049.9

Chymotrypsin Digestion

•*

RNETQHEPYPLM 1530.7

Both tryptic and chymotryptic PAP digests were analyzed by the QTRAP as described in
the experimental section. PI scans for oxonium ions 163, 366, and 292 are represented in
the above table. Certain EPI scans revealed glycopeptide information that allowed for the
assignment of both peptide and glycan.
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individuals, with each pool containing 180 micrograms of total protein. These pools
were also TCA precipitated and trypsin digested. The tryptic digestions were then treated
with PNGase F and permethylated. The permethylated glycans were analyzed by
MALDI-TOF/TOF (Figure 25 and Figure 26). Forty-three glycans were positively
identified from the EPS urine fluids, while direct EPS fluids yielded 24 glycan structures
(Table 11 and Table 12). For both EPS urine and direct EPS samples, mostly complex
subtype glycans were observed, with some high-mannose and hybrid subtypes
represented as well. There was extensive branching, sialylation, and fucosylation
detected in all sample sets (Table 11 and Table 12), indicating the complexity of these
fluids as well as the presence of many glycosylated proteins. Due to the high
concentration of the EPS fluids, the mass spectra resulted in very intense peaks, thus
allowing for MS/MS fragmentation analysis of several glycan structures. A
representation of MALDI-TOF/TOF LIFT spectra is shown in Figure 27, demonstrating
the fragmentation pattern of a permethylated complex, biantennary glycan containing one
terminal sialic acid by the MALDI-TOF/TOF instrument.

Detection of fucosylation differences among disease states by ClinProt data analysis
Clinprot software (version 2.0) was used to analyze MALDI-TOF spectra for EPS
urine PAP and EPS urine total glycan samples (Figure 21 and Figure 25). From these
analyses, we found that glycan structures without a core fucosylation were represented in
equivalent abundance among different disease states (i.e. normal, BPH, PCa), with an
example shown in Figure 28. In comparison, we observed an overall decrease in
intensity of fucosylated species in the cancer samples as compared to non-cancer
samples, which is exemplified in Figure 29. The fucosylated glycans found to be
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Figure 25. MALDI-TOF spectra of EPS urine N-glycans. Representative MALDI
spectra for permethylated N-glycans from non-PCa and PCa disease-defined EPS urine
pools are shown. Glycan structures corresponding to detected m/z peaks are listed in
Table 11.
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Figure 26. MALDI-TOF spectra for permethylated direct EPS N-glycans.
Representative MALDI spectra for permethylated N-glycans from low risk PCa and
intermediate risk PCa disease-defined direct EPS pools are shown. Glycan structures
corresponding to detected m/z peaks are listed in Table 12.
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Table 11. Permethylated glycans from EPS urine pools
Number

m/z

Proposed Glycan Structure

Sub-Type
*

1

1579.5

Number

m/z

Proposed Glycan Structure

a " * • •
Hiqh Mannose

M5N2

23

1783.557 M6N2

Hiqh Mannose

24

' ' • - -

x2 .

• * . .

3212.048 NeuAc2Gal2N3M3N2F

* . •••
2

Sub-Type
x2 .

Complex
.

3242.063 NeuAc2Gal3N3M3N2

Complex

: :;-.:
3

N/A

1835.595 N2M3N2F

25

3254.124 Hex3dHex1 HexNAc6NeuAc2

Complex
x2 .

4

1866.64

Gal1N2M3N2

Complex

26

" " • • •
Complex

3281.134 NeuAc2Gal2N4M3N2
x3
x3 .

5

Complex

1906.621 N3M3N2

27

3287.086 Hex6dHex3HexNAo6

Complex
x2 •

6

1987.672 M7N2

7

8

" "

High Mannose

28

3416.105 NeuAc2Gal3N3M3N2F

2039.664 GalN2M3N2F

Complex

29

3504.121 NeuAc1Gal4N4M3N2F

2069.675 Gal2N2M3N2

Complex

30

3603.148 NeuAc3Gal3N3M3N2

2080.682 N3M3N2F
*

10

Complex

31

3746.192 Hex6HexNAc10

Complex

32

3777.211 NeuAc3Gal3N3M3N2F

* . • •m
2185.703 Hex5HexNAc3NeuAc1

12

2212.706 Hex4dHex2HexNAc4

13

14

2227 728 NeuAc1Gal1N2M3N2

2244.735 Gal2N2M3N2F

N/A

33

3866.241 NeuAo2Gal4N4M3N2F

Complex

34

3952.261 Hex8dHex1 HexNAc7NeuAc1

Complex

Complex

35

36

" '

Complex

" • • » •
Complex

*

37

4314.459 Hex8dHex1 HecNAc7NeuAc2

16

2431.795 NeuAc1Gal2N2M3N2

Complex

38

4414.553 NeuAo4Gal4N4M3N2

Complex

39

4588.661 NeuAc4Gal4N4M3N2F

19

2605.853 NeuAc1Gal2N2M3N2F

2663.87

Gal2N3M3N2F2

Complex
•
Complex

•

:

•

"

"

x3 .

' " * ' • • •

x3 .

" " > > •

x2 .

"* , „ i

Complex

Complex

Complex

Complex

-

"

x2 t
18

" "
• • " » .

4227.458 NeuAo3Gal4N4M3N2F

Complex

Gal2N3M3N2F

'
•

4053.364 NeuAc3Gal4N4M3N2

2285.759 Gal1N3M3N2F

2489.82

Complex

x2 .

15

17

" *

•' • • •

2110.689 Hex4HexNAc5

11

• * . • •
Complex

*
9

I • « • •

" *

Complex

" "

Complex

Z ' * *

Complex

40

4676.711 Hex8dHex1 HexNAc7NeuAc3

Complex

41

4763.767 Hex11HexNac10

i :•*"

Complex

"

Complex

20

2792.908 NeuAc2Gal2N2M3N2

Complex

42

4833.816 Hex7dHex1HexNAc7NeuAc4

21

2966.969 NeuAc2Gal2N2M3N2F

Complex

43

5038.946 Hex8dHex1 HexNAc7NeuAc4

22

3054.996 NeuAc1Gal3N3M3N2F

Complex

Complex

x3 - !

" "

!

#

* • *
Complex

Identified m/z values were used for database searches, and corresponding masses that
could be assigned to a biologically relevant N-glycan structure are listed. An asterisk
denotes structures that are one representation of multiple possible glycoforms for a given
mass. The shown structure in these cases was chosen based on its apparent prevalence in
mammalian species. Cartoon representations are as follows:
• =GlcNAc, •
=Mannose, O =Galactose, A=Fucose, ^=NeuAc, • =GalNAc

117
Table 12. Permethylated glycans from low and intermediate direct EPS pools
Number

1

2

3

m/z

1375.757 M4N2

Hiqh Mannose
*

• . • • •

*

•

1579.865 M5N2

Hiqh Mannose

Hiqh Mannose
• • • •

1907.056 N3M3N2

Complex
.

5

• • •

1783.968 M6N2
*

4

Sub-Type

Proposed Glycan Structure

. : • • •

2156.185 NeuAc1Gal1N1M3N2F

N/A

• ;;...
6

2186.199 Hex5HexNAc3NeuAc1

7

2431.337 NeuAc1Gal2N2M3N2

8

2605.434 NeuAc1Gal2N2M3N2F

Hybrid

• ::•••
• ::•••
:

9

10

11

12

14

3504.924 NeuAc1GaUN4M3N2F

15

3603.954 NeuAc3Gal3N3M3N2

16

3777.038 NeuAc3Ga»N3M3N2F

18

• :!-

Complex

:
Complex

x2 •

• " • ,

,

x2 -

Z ' . . *

3242.771 NeuAc2Gal3N3M3N2

3415.851 NeuAc2Gal3N3M3N2F

17

Complex

: ::•"

2966.623 NeuAc2Gal2N2M3N2F

13

Complex

: : • • •

2792.524 NeuAc2Gal2N2M3N2

3055.688 NeuAc1GaBN3M3N2F

Complex

Complex

Complex

! : • -

• • : • • •

: :•••"
X2 .

" * . . «

«3.

• ; . . .

3867.088 NeuAc2Gal4N4M3N2F

Complex

Complex

Complex

Complex

4054.258 NeuAc3Gal4N4M3N2

Complex

« . •;..:
19

4228.405 NeuAc3GaBN4M3N2F

Complex

x3 r
20

i •> • •

4359.486 Hex8dHex4HexNAc8

Complex

* *•
21

4415.502 NeuAc4Gal4N4M3N2

Complex

22

4589.664 Hex9HexNAc8NeuAc2

Complex

23

4765.818 Gal4N4Gal4N4M3N2

Complex
x2 .

24

4952.625 Hex9dHex2HexNAc8NeuAc1

:

• ,

::-

Complex

Identified m/z values were used for database searches, and corresponding masses that
could be assigned to a biologically relevant N-glycan structure are listed. An asterisk
denotes structures that are one representation of multiple possible glycoforms for a given
mass. The shown structure in these cases was chosen based on its apparent prevalence in
mammalian species. Cartoon representations are as follows:
• =GlcNAc, •
=Mannose, O =Galactose, A=Fucose, •=NeuAc, • =GalNAc
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Figure 27. MALDI-TOF/TOF LIFT spectra of a permethylated glycan structure
from EPS urine. A representative LIFT spectra indicating the fragmentation of parent
mass 2430.78 detected in the spectra from Figure 25 is shown. Known masses of
common fragmentation patterns were used to annotate the data. Cartoon representations
are as follows: • =GlcNAc, O =Mannose, 0 =Galactose, A=Fucose, ^=NeuAc,
=GalNAc

•

Figure 28. Heat map overview of MALDI-TOF spectra for peak 2793. MALDI-TOF
spectra generated from EPS urine PAP samples were analyzed with Clinprot software,
indicating the intensity of the spectra from each sample cohort as compared to the next.
Each box represents spectra from one group, with normal being on top, BPH in the
middle, and prostate cancer on the bottom. Arrows show the peak height for each
corresponding heat map. Peak 2793 represents a complex, biantennary glycan with two
terminal sialic acids. Cartoon representations are as follows: • =GlcNAc, 9
=Mannose, 0 =Galactose, A=Fucose, ^=NeuAc, • =GalNAc
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Figure 29. Heat map overview of MALDI-TOF spectra for peak 2967. MALDI-TOF
spectra generated from EPS urine PAP samples were analyzed with Clinprot software,
indicating the intensity of the spectra from each sample cohort as compared to the next.
Each box represents spectra from one group, with normal being on top, BPH in the
middle, and prostate cancer on the bottom. Arrows show the peak height for each
corresponding heat map. Peak 2967 represents a complex, biantennary glycan with two
terminal sialic acids and a core fucose residue. Cartoon representations are as follows:
• =GlcNAc, O =Mannose, 0 =Galactose, A=Fucose, ^=NeuAc, D=GalNAc

differential between cancer and non-cancer samples were of the complex sub-type, with
various branching and terminal sialic acids.

6.4 Discussion
Using serum and plasma for biomarker discovery has proven to be difficult for
many laboratories, therefore demanding the need for enriched sources of lower abundant
proteins which are capable of differentiating between disease and non-disease states.
While it is commonly known that both tissues and proximal fluids are enriched for
potential biomarkers, the collection of such samples is not always within the parameters
of a given study. For our studies, we have found that EPS urine fluids are readily
obtained in the clinical setting, and are enriched for proteins directly related to the
prostate, thus making these fluids ideal for biomarker discovery for the detection of early
prostate cancer. In addition, EPS urines can be obtained at a routine physical exam,
making it not only ideal for discovery, but also for clinical applications as a source of
diagnostic markers for clinical assays. Direct EPS fluids are also enriched for prostatederived proteins and are a great discovery tool, however due to their method of
collection, they may not have utility for validation nor for future clinical assays.
Because glycosylation is known to be important to all aspects of cancer
progression83' 93,214? the glycan profiles of clinically-relevant samples may provide the
much needed diagnostic markers for early prostate carcinomas. While serum PSA is the
current FDA-approved biomarker for prostate cancer, it is not without faults. Serum PSA
has proven to be organ-specific, but is not cancer-specific, as elevated serum PSA levels
are detected with BPH conditions as well37"39. Additionally, a more current problem
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facing clinicians today is determining which patients have significant prostate cancer,
indicating they indeed need radical surgery and treatment as compared to patients who in
fact have indolent prostate cancer. In approximately 80% of radical prostatectomies it is
found that the patient's prostate cancer was not expected to be an aggressive lethal form
of tumor, despite their clinical risk factors indicating a different prognosis. This aspect
alone reiterates why better biomarkers are needed for distinguishing clinically significant
or aggressive forms of prostate cancers from more indolent tumors.
Being a glandular organ, the prostate is constantly secreting fluids full of proteins,
most of which are glycosylated. PSA and PAP are two prominent prostate-specific
proteins, and both are N-glycosylated, making them ideal targets for glycomic studies.
Based on preliminary studies, we have identified 36 different PAP glycoforms in EPS
urines, as compared to the 21 PAP glycoforms identified in our prior seminal plasma
studies. Nineteen of these structures overlap between seminal plasma and EPS urines
(Table 13). As seen with seminal plasma-derived PAP, the PAP glycoforms in EPS
urines are mostly of the complex subtype, with multiple branching, sialylation, and
fucosylation (Table 8). For EPS urine PSA, we observed 23 glycan structures, as
compared to the 40 different glycoforms identified for seminal plasma PSA (Table 9).
One explanation for this marked difference can be due to the dilution factor of EPS urines
as compared to seminal plasma, as well as other experimental aspects. Further analysis
of EPS urine PSA glycoforms will be necessary to appropriately compare these structures
to those observed in seminal plasma samples.
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Table 13. Shared PAP glycans between seminal plasma and EPS urine pools
Number

m/z

Glycan Structure

Sub-Type

* I'..' • •
1

Hiqh Mannose

1784.016 M6N2
•«

*

2

1987.958 M7N2

3

2070.189 Gal2N2M3N2

4

2244.268 Gal2N2M3N2F

High Mannose
: : • • •
Complex
: : • • •
Complex
*

5

2314.091 Hex5HexNAc5

6

2432 339 NeuAc1Gal2N2M3N2

7

2606.425 NeuAc1Gal2N2M3N2F

8

2793.503

• • • •
Complex
•

: : • • •
Complex

• -;;.-•• J
Complex
:

:: • • •

NeuAc2Gal2N2M3N2

Complex
•

9

2881.559 NeuAc1Gal3N3M3N2

10

2967.587 NeuAc2Gal2N2M3N2F

11

3055.647 NeuAc1Gal3N3M3N2F

•
•

Complex
*

; ; • • •
Complex

•

12

> • •

•

.• • •
Complex

x2 *

•;»••

x2 •

• • •a
• •

Complex

3242.719 NeuAc2Gal3N3M3N2

13

3416.793 NeuAc2Gal3N3M3N2F

14

3504.838 NeuAc1Gal4N4M3N2F

15

3603.894 NeuAc3Gal3N3M3N2

16

3777.971 NeuAc3Gal3N3M3N2F

17

3867.027 NeuAc2Gal4N4M3N2F

a - *•

Complex
'
Com plex

•

•

a a

• • •
Complex

. ...;»• •
Com plex
x2
m

x3
18

a*

4053.873 NeuAc3Gal4N4M3N2
x3

19

4227.294 NeuAc3Gal4N4M3N2F

Complex

-I'
a

* •

a-"*

Complex
*

Complex

Identified m/z values were used for database searches, and corresponding masses that
could be assigned to a biologically relevant N-glycan structure are listed. An asterisk
denotes structures that are one representation of multiple possible glycoforms for a given
mass. The shown structure in these cases was chosen based on its apparent prevalence in
mammalian species. Cartoon representations are as follows:
• =GlcNAc, •
=Mannose, O =Galactose, A=Fucose, ^NeuAc, • =GalNAc
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We also wanted to identify individual glycans attached to each N-linked site on
PAP using triple-quadrupole mass spectrometry, similar to those studies performed in
Aim I with seminal plasma fluids. Table 10 shows the structures and their respective
tryptic and chymotryptic peptides we observed using the precursor ion scan mode with
nanoLC-triple quadrupole MS/MS for diagnostic oxonium ions 163, 292, and 366.
While we did not identify as many glycopeptides as seen with our seminal plasma
studies, we were still successful in identifying three glycans, five tryptic glycopeptides,
and two chymotryptic glycopeptides. One explanation for less coverage with EPS urinederived PAP is the dilute nature of EPS urines as compared to seminal plasma. While
EPS urines are enriched for PAP as compared to serum or plasma, it is not as
concentrated as seminal fluid. Another possible explanation could be a decreased
efficiency of chymotryptic digestion with the EPS urine studies, as the limited coverage
observed arose from the chymotryptic digested experiments.
In addition to protein-targeted analyses, another useful glycomic approach
involves the examination of the global glycosylation patterns for a given sample set.
With this approach, one may observe an overall trend that differentiates between disease
states. We used the total glycan approach with both EPS urine and direct EPS samples
with the intention of examining the glycan structural isoforms (also termed glycoforms)
present and monitoring for any significant changes between disease states and differing
risk stratifications. Through our permethylation assays, we identified 43 glycoforms
derived from EPS urines and 24 glycoforms from direct EPS fluids (Table 11 and Table
12). It is imperative to note that the glycoforms observed are structural representations of
any number of anomeric isoforms. Therefore, while we are reporting a finite number of
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structures, there are possibly many more glycoforms present, which will require
additional analyses to define. When comparing non-PCa and PCa EPS urine PAP pools,
we see an overall trend of a decrease in fucosylated species in the PCa pools as compared
to the non-PCa pools, as represented by Figure 28 and Figure 29. Figure 28 depicts a
non-fucosylated, biantennary complex glycan, and shows that the peak intensities are
similar across the three groups, normal, BPH, and PCa. In contrast, Figure 29 shows the
same complex glycan with a core fucose residue, with a marked decrease in peak
intensity for the cancer group as compared to normal and BPH. These changes in
fucosylation complement other studies indicating changes in fucosylation with cancerous
states215"219. These data support the validity of EPS fluids as an excellent source for
identifying potential carbohydrate-based biomarkers.
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CHAPTER VI
CONCLUSIONS AND FUTURE DIRECTIONS

6.1 Aim I (Chapter III): Develop methodologies for the characterization of N-linked
glycans of prostate-specific antigen and prostatic acid phosphatase in seminal fluids.
A. The results from this aim indicate that N-linked glycosylation of seminal
plasma-derived PSA and PAP is very heterogeneous. In addition, we observed altered
glycosylation trends across normal, BPH, and PCa disease states for PAP.
B. Thiophilic adsorption chromatography (TAC) of disease-defined seminal
plasma pools successfully fractionated the protein mixture, providing further purified
forms of PSA and PAP. PAP did not bind the TAC resin, and therefore was collected in
the unbound fraction along with albumin and other non-binding proteins, as indicated by
western blot analysis. We also observed by western blot analysis that PSA elutes in two
separate fractions, those of 0.6M and 0.4M sodium sulfate concentration. We confirmed
PSA and PAP identity by in-gel trypsin digestion and peptide mass fingerprint (PMF)
analysis with MALDI-TOF mass spectrometry. This mass spectrometry analysis resulted
in the statistically significant identification of both PSA and PAP, without the detection
of any other proteins in the digested gel slice.
C. Normal phase HPLC separation of 2-AB derivatized N-linked glycans was
completed on PSA and PAP isolated from normal, BPH, and PCa seminal plasma pools,
with or without sialidase treatment. These results indicate clear differences among
disease states for PAP glycans, in particular when comparing normal and BPH samples to
cancer samples. A decrease in bi- and tetraantennary fucosylated structures as well as
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high mannose structures is observed for PAP arising from cancer samples as compared to
normal and BPH conditions. While no overall trend in disease-specific glycan changes
detected for PSA were observed for PSA glycans, the N-glycans identified were
consistent with previously reported structures observed for PSA, with high representation
of bi, tri-, and tetraantennary core fucosylated complex structures.
D. MALDI-TOF analysis of permethylated N-linked glycans yielded positive
identification of 40 PSA glycan structures and 21 PAP glycan structures. While the
majority of these structures are of the complex sub-type, we did observe a smaller
representation of both high-mannose and hybrid sub-types. The PSA and PAP N-glycan
structures identified by MALDI-TOF correlate well with the structures observed by our
HPLC separation, and remain consistent with previously published data.
E. Triple quadrupole mass spectrometry analysis of PAP glycopeptides enabled
us to determine which subtype of N-glycans are attached at each of the three N-linked
glycosylation sites for PAP. We observed bi- and triantennary sialylated structures at
Asn-62, bi- and tetraantennary sialylated structures at Asn-188, and high mannose
structures at Asn-301. Tryptic digestion of PAP did not allow for the elucidation of any
structures at Asn-188; however chymotryptic digestion of PAP created smaller
glycopeptides, therefore bringing the glycopeptides into the range of detection for the
triple quadrupole instrument. The observed high mannose structures present at Asn-301
and complex structures at Asn-188 correlate with previously published data on the crystal
structure of PAP. It was previously thought that high mannose structures must be present
at Asn-62; however we have confirmed the presence of complex structures at this N-

linked glycosylation site, with no evidence of a high-mannose structure present at this
site.

6.2 Aim II (Chapter IV): Establish expressed prostatic secretions as a source of
prostate specific antigen and prostatic acid phosphatase.
A. The results from this aim indicate that both EPS urine and direct EPS fluids
are indeed an enriched source of PSA and PAP. Both prostate cancer biomarkers are
readily detected in EPS fluids, and these fluids are compatible with our proteomic assays,
allowing for future, more in-depth analyses using EPS fluids.
B. A pre-DRE urine and a post-DRE "EPS" urine sample were collected from an
individual patient, on the same day, within one hour of each other. These samples were
analyzed and compared for their protein content by both 2D-PAGE and LC-ESI-MS/MS.
We observed relative protein differences between pre-DRE and post-DRE urines by
visualizing the spot patterns of 2D-PAGE separation of the proteins in each sample with
silver staining. Protein identification by mass spectrometry revealed an increase in the
number of significantly scored proteins present in the post-DRE urine as compared to the
pre-DRE urine. In addition, PSA and PAP were not identified in the pre-DRE urine;
however they were in the top 10 significant protein hits in the post-DRE urine.
C. Direct EPS fluid from one individual was analyzed by LC-ESI-MS/MS in
order to determine the proteins present in this prostatic fluid. We observed a large
number of proteins significantly identified in the direct EPS fluid, with PSA and PAP
both being in the top 10 significant hits. These results confirm that this fluid is indeed a
great source of PSA and PAP, and thus could be used in future proteomic and glycomic

studies with the intention of discovering enhanced biomarkers for the early diagnosis and
prognosis of prostate carcinomas.
D. Thiophilic adsorption chromatography (TAC) was utilized in order to
fractionate EPS urine disease-define pools with the intent of obtaining purified forms of
PSA and PAP for further analyses. PAP did not bind the TAC resin and therefore was
collected in the unbound fraction, as was detected by ID-PAGE and western blotting.
PSA eluted in the 0.6M, 0.4M, and 0.2M sodium sulfate fractions, which was also
determined by ID-PAGE and western blotting. MALDI-TOF PMF analysis was used to
confirm the identities of PSA and PAP which were run on ID-PAGE, excised, and in-gel
trypsin digested.
E. 2D-PAGE followed by western blotting was used in order to further examine
PSA and PAP characteristics in EPS fluids. A large pool of EPS urines were separated
by 2D-PAGE in duplicate, with one resulting gel being silver stained and the other gel
being transferred to PVDF membrane for western blot analysis of PSA and PAP. The
results from this analysis positively confirm the presence of multiple PSA and PAP
isoforms in EPS urines, most of which are likely glycoforms that can be targeted in
further studies.
F. ELISA analysis of PSA and PAP concentrations in individual EPS urine and
direct EPS samples was performed in order to determine PSA and PAP levels in prostatic
proximal fluids. We observed an overall decrease of both PSA and PAP levels in cancer
samples as compared to non-cancer samples, with a detection range of 10-40 ug/ml for
PSA and 3-10 ug/ml for PAP in EPS urines and a range of 80-120 ug/ml for PSA and 2040 ug/ml for PAP in direct EPS fluids. These results indicate that PSA and PAP are less
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prevalent in cancerous tissue as compared to normal and BPH tissues, however larger
sample cohorts are necessary in order to truly understanding the status of these
biomarkers in the diseased prostate.

6.3 Aim III (Chapter V): Application of new methodologies to expressed prostatic
secretions for prostate cancer glycoprotein biomarker discovery.
A. The results from this aim indicate that protein-specific and total glycomic
analyses can be performed using EPS urine and direct EPS fluids. We positively
identified N-linked glycans for both PSA and PAP derived from EPS urines. In addition
we observed a number of N-linked glycans in disease-defined pools of EPS urine and
direct EPS fluids, indicating the feasibility of discovering new candidate carbohydratebased biomarkers in EPS fluids for the early diagnosis and prognosis of prostate
carcinomas.
B. Normal, BPH, and PCa disease-defined pools of EPS urines were generated
and subsequently fractionated using thiophilic adsorption chromatography (TAC). As
seen previously, PAP did not bind the TAC resin and was collected in the unbound
fraction, while PSA eluted in the 0.6M, 0.4M, and 0.2M sodium sulfate fractions. PSA
and PAP identities were positively confirmed in their respective fractions by silver
staining and western blotting.
C. MALDI-TOF analysis of permethylated N-linked glycans was performed for
PSA and PAP derived from EPS urine disease-defined pools (normal, BPH, PCa). We
observed a total of 23 glycoforms for PSA and 36 glycoforms for PAP, with mostly
complex subtypes being represented. High mannose and hybrid subtypes were also
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present for PSA, with only the addition of high mannose structures positively identified
for PAP. There were a number of glycoforms for PAP that the subtype could not be
determined as either complex or hybrid. For both PSA and PAP, the complex glycans
observed often contained terminal sialic acid residues and core fucose residues.
D. Triple quadrupole MS was used in the precursor ion scanning mode to
examine the N-glycan subtypes present at each N-linked glycosylation site of PAP. After
multiple experiments using the 163, 292, and 366 diagnostic ion masses, and using both
trypsin and chymotrypsin digested PAP, we observed biantennary complex structures at
Asn-62 and high mannose structures at Asn-301. We were unable to confirm the
presence of any structures at Asn-188, which had proven to be difficult in our previous
analyses using seminal plasma-derived PAP. These differences are likely due to either
sample concentration, protease digestion efficiency, or both.
E. Total glycan analysis of permethylated N-linked glycans from EPS fluids was
performed using MALDI-TOF. EPS urine pools defined as non-PCa and PCa resulted in
a total of 43 glyco forms, while direct EPS pools (low risk PCa and intermediate risk PCa)
resulted in 24 glycoforms. Again, complex N-linked glycan subtypes comprise the
majority of glycoforms observed, with high mannose and hybrid structures also
represented. Due to the high concentration of glycans present in the sample,
fragmentation of a subset of individual glycoforms was accomplished using MALDITOF /TOF LIFT. This type of fragmentation is typically not performed, as ESI-MS/MS
with an ion trap is the preferred instrumentation used for glycan fragmentation. We
detected near complete fragmentation by manual annotation of the spectra, and likely
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could confirm the presence of complete fragmentation with appropriate bioinformatic
tools.
F. Clinprot software data analysis was performed on EPS urine PAP glycan and
EPS urine total MALDI-TOF spectra. We observed an overall trend of decreased
fucosylation in cancer samples as compared to normal and BPH samples. These results
indicate that for PAP, and potentially other glycoproteins derived from the prostate, there
is less fucosylation occurring in a cancerous prostate. These glycan targets will be useful
for examining larger sample cohorts and determining the utility of a glycan-based
biomarker for the detection or early prostate carcinomas, as well as distinguishing
between significant and insignificant prostate carcinomas.

6.4 Concluding Remarks and Future Directions of Aims I, II, and III
Based on our present studies, we have gained knowledge about and catalogued
the type of N-linked glycoforms attached to PSA and PAP in prostatic fluids.
Additionally we have preliminary data confirming N-linked glycan differences among
disease states (normal, benign, PCa) for PAP in seminal fluid and EPS. However, more
in-depth studies are necessary to further elucidate novel candidate biomarkers for the
early diagnosis and prognosis of prostate cancer. It has become common knowledge that
while serum PSA is the best biomarker currently available for the detection of prostate
carcinomas, especially when it is used in conjunction with a DRE exam, there is still a
pressing need for better biomarkers. Many prostate cancers being detected today are in
fact indolent diseases, and do not pose any lethal danger to the patient. Therefore, many
patients are undergoing unnecessary biopsies, surgeries, and treatments, all of which can
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cause physical and emotional hardships. Additionally, some patients suffer more from
the resulting health complications that can develop post-treatment or post-surgery than
they would have if their prostate cancer had remained untouched. A new classification
scheme is being developed which differentiates between significant and insignificant
prostate carcinomas. Under these new definitions, significant disease represent tumors
which are most likely to progress to more aggressive cancers and therefore need to be
treated, while insignificant disease represent tumors are least likely to progress and not
affect the patient's life expectancy or livelihood. However, these classifications are
currently only determined after the patient has undergone a radical prostatectomy, and
examination of the removed prostate by a highly-specialized pathologist. In order to help
future patients, a way to better determine these classifications prior to surgery or several
biopsies is essential.
Because protein glycosylation has been shown to be involved in every aspect of
cancer progression , it is plausible that the altered glycans can be detected reliably,
further validated, and ultimately used in high-throughput clinical-based assays. PSA has
one N-linked glycosylation site, while PAP contains three N-linked glycosylation sites,
all of which have been confirmed to be occupied by glycans120,124'125. PAP has been
extensively reported in the literature to have wide-spread distribution throughout human
tissue '

, with past clinical assays relying solely on its enzymatic activity. Eventually

it was found that the PAP activity being assayed in blood could not be correlated back to
the prostate as the sole source of PAP. We have circumvented this issue by focusing on
forms of PAP derived directly from prostatic fluids instead of from serum or plasma. Not
only are we now analyzing prostate-specific PAP, these fluids are enriched for PAP as

compared to serum or plasma. For PSA, while it has been shown to be prostate-specific,
and therefore still has high specificity when used in serum-based clinical assays, we are
able to obtain enriched PSA by using our prostatic fluids.
Another advantage we have lies in our vast biorepository of seminal fluids and
expressed prostatic secretions, with EPS collection an ongoing process with growing
numbers of collections. In addition, we are collecting EPS fluids for different cohorts of
patients, including but not limited to healthy, normal patients and patients with BPH or
prostate cancer. We also have been able to classify the prostate cancer samples into
different risk stratifications, giving us many different possible cohorts to examine for
glycosylation changes to PSA and PAP.
Glycomic analyses do not always have to be performed on individual proteins in
order to provide useful information, in fact, analysis of global glycomic changes have
been reported175'176. These methods search for an overall alteration to glycosylation
patterns in a given disease state which, in turn, is reflective of all proteins contributing to
the glycosylation changes. Our studies have provided basic knowledge of the most
abundant glycan structures present in EPS fluids, as well as those attached specifically to
PSA and PAP. However, deeper analyses are necessary in order to identify less common
structures, as well as to determine the changes that are occurring between disease states.
We have observed trends indicating a decrease in overall levels of fucosylation when
comparing prostate cancer samples to normal and BPH samples. Now that we have
candidate glycoforms, additional analyses will be needed to confirm whether the
differences seen are maintained in larger cohorts of individual samples. To do so,

optimization of current methodologies as well as the addition of enhanced glycomic
strategies is required.
First, permethylated N-linked glycans can be readily detected by MALDI-TOF.
This derivatization method stabilizes the glycans, more specifically the terminal sialic
acid residues, as well as simplifies the resultant spectra by producing only sodium ion
adducts. However, our current scheme utilizes a well-established liquid-phase
permethylation technique195 that does not allow for high-throughput analyses. While we
are able to obtain robust results from this method, we can only analyze small numbers of
samples at one time (n<=5), and it is a slow, tedious process. To overcome this timeconsuming dilemma, a solid-phase permethylation approach may be implemented. This
method calls for either the use of capillary columns or spin-columns, both of which allow
for more rapid permethylation of each sample, and for higher amounts of samples to be
processed at one time '

. In addition to its high-throughput nature, the solid-phase

protocol is highly quantitative and allows for the higher recovery of sample, therefore
decreasing the amount of starting material needed for satisfactory results223. We would
like to utilize the spin-column method, where the limiting factor is the number of sample
holders in the centrifuge rotor (i.e. n=18-30). In this method, microcentrifuge spincolumns are used for the clean-up steps of the cleaved glycans prior to permethylation
and the permethylation reaction itself. Sodium hydroxide beads bathed in acetonitrile are
added to empty spin columns with an optimal bed volume, washed with DMSO, and the
sample combined with iodomethane (source of methyl groups) is applied to the column
up to 8 times repeatedly, and in a matter of minutes, the reaction is complete and ready
for the final liquid-liquid (water-chloroform) extraction step. Not only does this method

require less time at the bench, it has also been shown to provide more complete
permethylation as compared to the liquid-phase method .
After employing the front-end sample preparative steps in a more rapid fashion,
the mass spectrometry platforms need to be addressed. Our current MALDI-TOF
analysis provides us with intact glycan information, giving us the mass of the parent
structure which we can use to search a public database for potential structural matches.
However, at this time, we are unable to determine the linkage information by MS/MS on
the MALDI-TOF instrument for most samples. Fragmentation analysis with an ESI-LIT
MS/MS instrument (i.e. ThermoFinnegan LTQ or Applied Biosystems QTRAP) will
allow for input of small quantities of samples and subsequently resulting in the structural
information necessary to determine monosaccharide linkage data.
Once the data has been collected, computer software programs are indispensable
in the actual assignment of the structural linkages. One example of such commercially
available software is SimGlycan (Applied Biosystems/PremierBiosoft), which takes
MS/MS data directly from Applied Biosystems (ABI) and Bruker instruments, as well as
accepts data from other mass spectrometers after a file conversion. The software needs
user input of a number of factors such as the parent mass of the fragmented structure, the
charge state of the parent mass, whether or not the structure has been derivatized. Also,
if the experimental spectrum is derived from a glycopeptide instead of a cleaved glycan
structure, then the user will need to also input peptide information such as the amino acid
sequence and any peptide modifications that may be present. The software then takes all
of the MS/MS masses and searches an internally developed glycan database, annotates
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the data, and provides the user with a list of potential glycoforms that can fit the spectrum
data provided.
Finally, after candidate glycoforms have been discovered by the above sample
preparative steps and mass spectrometry analyses, validation of such structures is
necessary, and subsequently clinical assays need to be developed that can accommodate
the high-throughput detection of the given carbohydrate markers. One particular assay
that will fit these criteria is the lectin fluorophore-linked immunosorbent (FLISA)
assay199'216. This type of plate-based assay is similar to a sandwich ELISA assay in the
sense that an antibody is used to capture the target protein, and then a lectin is used to
detect and measure the specified monosaccharide on that protein, versus using a second
antibody to detect and measure the protein of interest. For example, since the
fucosylation state of various N-linked complex glycans is seen to be differential between
disease states, this is a good candidate monosaccharide target to begin with. For the
lectin FLISA, it is imperative to make sure that the capture antibody be modified if it is a
glycosylated protein, therefore in the case of a fucose-targeted assay, the antibody will
need to be defucosylated using a competing sugar such as alpha-galactose216. After the
plate wells are coated with the modified capture antibody, the experimental sample (i.e.
serum, EPS urine fluid) is added to the wells and allowed to bind prior to the addition of
a conjugated lectin (i.e. biotin-AAL). Finally the bound lectin is detected using an
appropriate system (i.e. conjugated-streptavidin) and the signal intensity is measured with
the preferred system216. With this lectin FLISA assay, the amount of fucosylation in a
given sample can be detected, and like a protein-based biomarker, a threshold can be set
indicating at what level the fucosylation indicates disease versus non-disease. For some

cases, it may not simply be one monosaccharide contributing to the disease state, and
therefore a panel of monosaccharides will be measured and used together to determine
the disease state. In the case of prostate cancer, ideally these glycan changes will allow
for differentiation between insignificant and significant disease, allowing for better
patient prognosis profiles and therefore decreasing the number of unnecessary biopsies,
treatments, and radical surgeries in men afflicted with prostate carcinomas.
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